The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Phase: PHASE1
Conditions: Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

 
 
The TEEL Study: A Phase I Trial of Tamoxifen with Ribociclib (LEE011) in Adult 
Patients with Advanced ER+ (HER2 Negative) Breast Cancer 
NCT02586675 
 
Version 12.0 
September 14, 2016 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 1 
 
 
 
TITLE PAGE  
The TEEL Study: A Phase I trial of Tamoxifen with Ribociclib (LEE011) in adult patients with 
advanced ER+ (HER2 negative) breast cancer. 
 
 
Protocol:  
MCC 18332 
 
 
Chesapeake IRB Pro00015228 
 
 
Principal Investigator: 
  
 
Co-Investigators: 
 
 
  
  
 
 
 
 
 
 
 
 
Statistician: 
 
 
Experimental Therapeutics Program 
H. Lee Moffitt Cancer Center 
12902 Magnolia Drive 
Tampa, FL 33612 
& 
Comprehensive Breast Program 
Moffitt McKinley Outpatient Center 
10920 N. McKinley Dr.  
Tampa, FL 33612 
 
Study Site Contact: 
 
 
Protocol Version 12 Date: September 14, 2016 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 2 
 
 
TITLE PAGE .............................................................................................................................................. 1 
SYNOPSIS ................................................................................................................................................... 5 
Patient Population ................................................................................................................................. 5 
Type of Study ......................................................................................................................................... 5 
Prior Therapy......................................................................................................................................... 5 
Rationale for Study ................................................................................................................................ 5 
Rationale for the combination of CDK4/6 inhibitors with Tamoxifen plus goserelin ................ 6 
Type of Study: ........................................................................................................................................ 7 
Phase I  ............................................................................................................................................... 7 
Phase Ib dose expansion ................................................................................................................... 7 
Phase I Study drugs (ribociclib dose may change depending on results of phase I) .................. 8 
Safety Evaluation ................................................................................................................................... 8 
Dose and Treatment Schedule .............................................................................................................. 8 
Prohibited Medications: ........................................................................................................................ 9 
Statistical Considerations ...................................................................................................................... 9 
Efficacy Evaluation .............................................................................................................................. 10 
DEFINITIONS: ......................................................................................................................................... 11 
1 
BACKGROUND AND RATIONALE ....................................................................................... 12 
1.1 
Introduction ............................................................................................................................ 12 
1.2 
Tamoxifen ................................................................................................................................ 13 
1.3 
CDK Inhibitors ....................................................................................................................... 13 
1.4 
Role of the CDK4/6 pathway in breast cancer ..................................................................... 14 
2 
INTRODUCTION TO INVESTIGATIONAL TREATMENT(S) AND OTHER STUDY 
TREATMENT(S) ......................................................................................................................... 15 
2.1 
Overview of RIBOCICLIB .................................................................................................... 15 
2.1.1 
 Nonclinical pharmacokinetics and metabolism ............................................................. 16 
2.1.2 
 Clinical experience of RIBOCICLIB .............................................................................. 17 
2.1.3 
 Clinical safety of RIBOCICLIB ...................................................................................... 17 
2.1.4 Clinical efficacy of RIBOCICLIB ........................................................................................ 21 
2.1.5 
 Clinical pharmacokinetics of RIBOCICLIB .................................................................. 21 
2.2 
Overview of Tamoxifen .......................................................................................................... 21 
2.3 
Potential for a drug-drug interaction between ribociclib and Tamoxifen ......................... 22 
2.4 
Overview of goserelin ............................................................................................................. 23 
2.4.1 
Very Low potential for drug-drug interactions with goserelin ..................................... 24 
2.5 
Rationale for the combination of CDK4/6 inhibitors with Tamoxifen plus goserelin ...... 24 
3 
OBJECTIVES .............................................................................................................................. 25 
3.1 
Primary Objective .................................................................................................................. 25 
3.2 
Secondary Objectives: ............................................................................................................ 25 
4 
INCLUSION CRITERIA ............................................................................................................ 25 
5 
EXCLUSION CRITERIA ........................................................................................................... 27 
6 
PATIENT REGISTRATION: .................................................................................................... 28 
7 
TREATMENT PLAN:................................................................................................................. 29 
7.1 
Dose Modifications.................................................................................................................. 30 
7.2 
Ribociclib dose adjustment and management recommendation for all other adverse 
reactions ................................................................................................................................... 36 
7.3 
Adjustment of Starting Dose in Special Populations ........................................................... 38 
7.4 
Follow-up for toxicities ........................................................................................................... 38 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 3 
 
 
7.5 
Concomitant Medications ...................................................................................................... 38 
7.6 
Permitted concomitant therapy requiring caution .............................................................. 39 
7.7 
Prohibited concomitant therapy ............................................................................................ 39 
7.8 
Packaging and labeling........................................................................................................... 41 
7.9 
Drug Supply and Storage ....................................................................................................... 41 
7.10 
Study Drug Compliance and Accountability ........................................................................ 42 
8 
TREATMENT PLAN .................................................................................................................. 42 
8.1 
Study Design: .......................................................................................................................... 43 
8.2 
Dosing regimen ....................................................................................................................... 44 
8.3 
General dosing guidelines ...................................................................................................... 44 
8.4 
Safety Evaluation .................................................................................................................... 45 
8.5 
STUDY CALENDAR ............................................................................................................. 46 
8.6 
Efficacy Evaluation for Dose I Expansion Cohorts: ............................................................ 49 
8.7 
Treatment Duration................................................................................................................ 50 
9 
PHARMACOKINETICS ............................................................................................................ 50 
10 
STATISTICAL CONSIDERATIONS ....................................................................................... 51 
10.1 
Statistical Considerations for Phase I escalation  Study ..................................................... 51 
10.2 
Statistical Considerations for Phase Ib Dose expansion Study ........................................... 52 
10.3 
Statistical Considerations for Safety ..................................................................................... 52 
11 
CRITERIA FOR RESPONSE, PROGRESSION AND RELAPSE ........................................ 53 
11.1 
Criteria for Target Lesions .................................................................................................... 53 
11.1.1 Measurable disease .............................................................................................................. 53 
11.1.2. Non-measurable disease ..................................................................................................... 53 
11.1.3. Target lesions ...................................................................................................................... 53 
11.1.4 Non-target lesions ................................................................................................................ 54 
11.2 
Evaluation of response criteria .............................................................................................. 54 
11.2.1  Target lesions ..................................................................................................................... 54 
11.2.2 Evaluation of non-target lesions ......................................................................................... 54 
11.3 
Evaluation of Best Overall Response .................................................................................... 55 
11.4 
Guidelines for Evaluation of Measurable Disease ............................................................... 55 
11.4.1 Clinical Lesions .................................................................................................................. 56 
11.4.2 Conventional CT and MRI ............................................................................................... 56 
11.5 
Confirmation Measurement/Duration of Response ............................................................. 56 
11.5.1 Duration of Overall Response .......................................................................................... 56 
11.5.2 Duration of Stable Disease ................................................................................................ 56 
11.6 
Evaluable disease .................................................................................................................... 56 
12 
ADVERSE EVENT REPORTING ............................................................................................ 56 
12.1 
Adverse Event reported for RIBOCICLIB .............................. Error! Bookmark not defined. 
12.2 
Adverse Event Characteristics .............................................................................................. 57 
12.3 Investigator Reporting:  Novartis instructions for rapid notification of serious adverse events 57 
13 
DATA SAFETY MONITORING ............................................................................................... 58 
13.1 
Data Reporting ........................................................................................................................ 60 
13.2 
Study Suspension/Termination .............................................................................................. 60 
13.3 
Trial Discontinuation.............................................................................................................. 60 
14 
INCLUSION OF WOMEN AND MINORITIES: .................................................................... 60 
15 
CORRELATIVES ....................................................................................................................... 60 
15.1 
Biomarkers in a sub-group of patients ................................................................................. 60 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 4 
 
 
15.2 
Pharmacodynamics biomarker assessments ............................ Error! Bookmark not defined. 
16 
REFERENCES ............................................................................................................................. 64 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 5 
 
 
SYNOPSIS 
 
Title: 
The TEEL Study: A Phase I trial of Tamoxifen with Ribociclib (LEE011) in adult patients with 
advanced ER+ (HER2 negative) breast cancer. 
 
Patient Population 
Patients with estrogen or progesterone receptor positive, HER2-negative advanced (metastatic) breast 
cancer that are in one of the following populations 
 
Premenopausal Women: 
A) Premenopausal women who received adjuvant Aromatase Inhibitor and Ovarian Suppression (AI + OS) 
in the adjuvant setting and completed at least 12 months of hormonal therapy. 
B) Premenopausal patients who have de-novo metastatic disease (metastatic disease at presentation).  
C) Premenopausal women who have not received Tamoxifen in the metastatic setting, but have received up 
to two lines of chemotherapy. 
 
Post-Menopausal Women or Men 
D) Postmenopausal patients who have progressed on first-line or second-line therapy with an aromatase 
inhibitor in the metastatic setting 
E) Postmenopausal patients who have recurred while on or after completion of adjuvant treatment with 
aromatase inhibitors (they have completed at least one year of adjuvant AI in the adjuvant setting before 
progression on AI). 
F) Postmenopausal patients who are not considered candidates for treatment with an aromatase inhibitor by 
their oncologist , patients not willing not to go on to AI, or were intolerant to AI 
G) Post-menopausal women or men who have been treated with up to three lines in the escalation arm and up 
to two lines of chemotherapy in the dose expansion arm in the metastatic setting. 
 
Type of Study 
Open labeled, non-randomized; phase I dose escalation followed by phase Ib dose expansion 
 
Prior Therapy 
• 
Progression on any aromatase inhibitor for metastatic disease  
• 
Recurrence >12 months after commencement of adjuvant aromatase inhibitors  
• 
Patients are allowed (but not required) to have up to two prior chemotherapy regimens for metastatic 
disease 
 
Rationale for Study 
Cell cycle progression is directly regulated by cyclin-dependent serine-threonine protein kinases. The 
cyclin D proteins are important in cancer, as their abundance and functions are regulated by extracellular 
growth factor and adhesion signaling. The cyclin D proteins act through the CDK4 and CDK6 protein 
kinases to promote G1 progression (1). CDK4 and CDK6, in turn, hyperphosphorylate and activate the 
retinoblastoma protein Rb to promote cell cycle entry and cell proliferation. Consistent with their having 
an important role in human cancer, focal copy number abnormalities that result in increased CDK activity 
are among the most commonly described genetic events observed in diverse tumor types; these events 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 6 
 
 
include amplifications of the genes that encode cyclin D1 or CDK4, and deletions affecting the CDKN2A 
locus, which encodes the p16INK4a inhibitor of CDK activity (2-4).  
 
Data from The Cancer Genome Atlas highlight the importance of the Cyclin/CDK/Rb pathway in breast 
cancer (2, 3). Abnormalities that result in CDK activation are highly enriched in the luminal A and B 
molecularly defined subgroups, ~85% of which were ER+/Her2- (5). Cyclin D1 amplifications were 
observed in 29% and 58% of the luminal A and B subtypes, respectively, and CDK4 amplifications were 
observed in 14% and 25% of luminal A and B subtypes, respectively. Luminal A subtype tumors also 
have loss of CDKN2C, which encodes p16Ink4a, a CDK inhibitor. The luminal subtypes also maintain 
expression of Rb, which would be essential for benefit from treatment with a CDK4/6 inhibitor (2-4). 
PD0332991 is an oral, potent, selective inhibitor of CDK4/6 that was shown to inhibit proliferation and 
induce apoptosis in multiple preclinical models of endocrine-resistant breast cancer, both in vitro and in 
vivo (11, 4). In the clinic, PD0332991 was studied in a randomized Phase II study in combination with 
the non-steroidal aromatase inhibitor letrozole. This combination significantly prolonged median 
progression free survival in postmenopausal women with locally recurrent or advanced ER+/HER2- 
breast cancer treated in the front-line setting (median PFS 26.1 vs 7.5 months, reported in Finn et al (6). 
 
Most breast tumors that initially respond to anti-estrogen therapy acquire resistance in time. Given the 
above pre-clinical data, there may be benefit from a combination of Tamoxifen and Ribociclib, in women 
with hormone sensitive tumors as well as those whose tumors became unresponsive. Current and recently 
completed studies restrict CDK trials and limit the patient population to only postmenopausal patients but 
it is well known that younger, pre-menopausal and peri-menopausal patients often have more 
“aggressive” disease and more endocrine-resistant disease an d this combination may be very helpful in 
delaying endocrine resistance in this patient population. 
 
Rationale for the combination of CDK4/6 inhibitors with Tamoxifen plus goserelin 
Multiple adjuvant studies have described amenorrhea as a positive prognostic factor in patients with 
overall survival after adjuvant chemotherapy. Based upon a number of adjuvant studies, the NCCN 
guidelines recommend goserelin to be strongly considered in premenopausal women who are 
menstruating despite receiving chemotherapy (7). In a retrospective study done at one hospital, over 150 
patients with stage Ia to IIIa ER + breast cancer who received goserelin or chemotherapy were reviewed. 
Survival analysis was assessed by the Kaplan-Meier method. Survival at 11 years was significantly better 
in the goserelin group (P < 0.0012). The lifetime lost was lower in the goserelin group (42 months vs. 66 
months). The quality adjusted survival (QAS) of patients who received goserelin was longer (122.5 ± 6.3 
vs. 112.2 ± 6.7 months. The quality-adjusted life-year was higher in the goserelin group. Goserelin 
therapy results in better survival and higher utility-weighted life-years, and is more cost-effective (8). We 
plan to add goserelin to all women who are not postmenopausal. We estimate that of the 40 patients on 
study, approximately 20 will not meet the standard criteria of a post-menopausal state (no menstrual 
cycles for greater than 12 months and FSH of > 40). We will not stratify for menopausal status. This 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 7 
 
 
study is inclusive of all women regarding of menopausal status and explores the combination of 
Tamoxifen with this CDK4/6 inhibitor. 
We will additionally explore two cohorts in the Phase Ib expansion. Having a continuous dosing cohort 
has multiple advantages. There is sustained inhibition of the cell cycle and less AEs. This cohort will 
allow us to further explore a cohort with increased safety and better patient compliance. Patients will not 
have to remember whether they are on the “on week” or the “off week.” Continuous dosing was done in 
Ph I CLEE011X2101 and both continuous and intermittent dosing revealed increased rates of grade 3 or 4 
neutropenia rates at day 15 of every cycle on doses of 600 mg of  Ribociclib and higher. At lower doses, 
ribociclib had lower rates of neutropenia and continuous dosing should be tolerated. 
 
Type of Study:   
   
Open labeled, non-randomized, Phase I escalation study with a Phase Ib dose expansion. 
 
Phase I 
 
The phase I portion of the study is a dose escalation to confirm the safety of the combination and to 
determine the MTD and the RP2D for ribociclib with Tamoxifen. 
 
Phase I will be conducted in all patients with HR+/HER2- locally advanced or metastatic breast cancer 
with any prior endocrine therapy and up to three prior cytotoxic chemotherapy regimens administered in 
the metastatic or locally advanced setting. 
 
Phase Ib dose expansion 
Phase I trials are increasingly including dose-expansion cohorts (Ib) after the maximum-tolerated dose 
(MTD) has been reached to better characterize the toxicity profile and identify early signs of efficacy 
within this specific disease population. Our goal is to assess the anti-tumor activity Ribociclib + 
Tamoxifen and to further evaluate their safety in adult patients with HR+/HER2- locally advanced or 
metastatic breast cancer. Patients in the phase 1b expansion will have the same exclusion and inclusion 
criteria except that they will only be allowed to have up to two lines of cytotoxic chemotherapy in the 
metastatic setting. 
 
Tamoxifen will be administered orally according to the standard regimen used in clinical practice (20 mg 
oral QD).  Ribociclib will be administered orally, once daily for 21 consecutive days followed by a 7-day 
planned break (28-day cycle). In the continuous dose cohort, ribociclib will be administered daily (QD) 
without a break in each cycle. Tamoxifen will be administered in combination with ribociclib until 
disease progression or if unacceptable toxicity occurs that precludes any further treatment and/or if 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 8 
 
 
treatment is discontinued at the discretion of the investigator or the patient, or the patient’s death, 
whichever occurs first.  
 
Phase I Study drugs (ribociclib dose may change depending on results of phase I) 
 
TAMOXIFEN: 20 mg po daily  
 
RIBOCICLIB: Phase I: starting at a dose of 400 mg po for 21 days of a 28-day treatment cycle;  increased 
to 400 mg po daily (continuous dosing);  increased to  600mg po daily for 21 days of a 28 day cycle.  
 
Phase 1b expansion will look at two cohorts: 600 mg po for 21 days of a 28 day cycle with Tamoxifen 
and a continuous dosing cohort of ribociclib 400 mg daily with Tamoxifen. 
 
Please note, that per NCCN guidelines for treatment of ER positive breast cancer, Goserelin acetate 
(Zoladex) (3.6 mg subcutaneous every 28 days) will be given per SOC practice to pre-menopausal and 
peri-menopausal women. This is standard of care for the treatment of pre- and peri- menopausal women 
and is not considered part of the study. The metabolism of goserelin is not CYP-mediated; rather 
hydrolysis of C-terminal amino acids is the major clearance mechanism. Based on the available 
information, goserelin is not expected to affect the metabolism of ribociclib nor be affected by co-
administered drugs.  
 
 
Safety Evaluation 
Toxicity assessment, interim history and physical exam, CBC and chemistry profile weekly in cycle 1, 
then at day 1 of each cycle thereafter. Adverse Events and other symptoms will be assessed continuously 
and graded according to the NCI Common Toxicity Criteria, (CTCAE) v.4. Patients will be followed for 
evaluation of safety for at least 30 days after the last dose of study drug or until resolution of the AE. Any 
study drug-related serious adverse events will be followed until resolution, return to baseline grade, or 
deemed irreversible by the investigator. 
 
Dose and Treatment Schedule 
 
No of pts 
Cohort Level 
Ribociclib 
Tamoxifen 
3-6 (phase 1) 
1 
400 mg oral days 1-21,  
followed by 1 week break 
 20mg oral daily 
3-6 (phase 1) 
2 
400 mg continuous 
20 mg oral daily 
3-6 (phase 1) 
3 
600 mg oral day 1-21 
followed by 1 week break 
20 mg oral daily 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 9 
 
 
15 (dose 
expansion) 
Phase Ib dose 
expansion 
600 mg oral day 1-21 
followed by 1 week break 
20 mg oral daily 
15 (dose 
expansion) 
Phase Ib –dose 
continuous dosing 
cohort 
400 mg oral daily 
20 mg oral daily 
* Goserelin acetate (Zoladex) 3.6 mg subcutaneous every 28 days will be given per NCCN guideline to 
pre-menopausal and peri-menopausal patients as described above. We will define this further in the full 
protocol. 
* If the daily dosing is too bone marrow suppressive, then this arm will switch to 400 mg oral days 1-21, followed 
by 1 week break  of a 28 day cycle. 
 
Prohibited Medications: 
• 
No other chemotherapy, hormonal therapy, radiotherapy, or experimental anticancer medications 
for the primary disease will be permitted while the patient is on study.  
• 
Strong inhibitors or inducers of CYP3A4/5 
• 
Substrates of CYP3A4/5 with narrow therapeutic windows 
• 
Medications that carry a strong risk for QT prolongation 
• 
Herbal medications/preparations not prescribed by treating MD 
 
 
 
Statistical Considerations 
 
 
Patient Population: 
Patientswith estrogen and/or progesterone receptor positive, HER2-negative advanced (metastatic) breast 
cancer that are in one of the following populations 
Pre-menopausal Women: 
A. Pre-menopausal women who received adjuvant Aromatase Inhibitor and Ovarian Suppression (AI 
+ OS) in the adjuvant setting and completed at least 12 months of hormonal therapy. 
B. Pre-menopausal women who have never been treated with endocrine therapy with de-novo 
metastatic disease.  
C. Pre-menopausal women who have not received Tamoxifen in the metastatic setting, but have 
received up to two lines of chemotherapy for dose expansion and up to three lines for dose 
escalation. 
Post-Menopausal Women or Men 
D. Post-menopausal women or men who have progressed on first-line or second-line therapy with an 
aromatase inhibitor 
E. Post-menopausal women or men who have recurred while on or after completion of adjuvant 
treatment with aromatase inhibitors (they have completed at least one year of adjuvant AI in the 
adjuvant setting before progression on AI). 
F. Post-menopausal women or men who are not considered candidates for treatment with an aromatase 
inhibitor by their oncologist, refused AI, or intolerant to AI  
G. Post-menopausal women or men who have been treated with up to two lines of chemotherapy for 
dose expansion and up to three lines for dose escalation in the metastatic setting. 
 
Total number of patients: 40 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 10 
 
 
 
Number of Centers:  1 (will be adjusted, increased if accrual goals are not met). 
 
 
Sample Size Justification (will be updated by statistician):   
For a total of 40 subjects, about 9-12 will be accrued during phase 1 portion and about 30 patients for 
the phase 1b expansion. 
 
Part 1: phase 1 portion:  
We will evaluate the first 9-12 patients in the phase I portion for safety. 
The Primary objective is safety. 
 
Part II: phase Ib expansion: 
For the phase one expansion we will include pre- menopausal women,  post-menopausal women, and 
menevaluated as one group. We will further evaluate both a three weeks on and one week off cohort (i.e. 
once daily for 21 consecutive days followed by a 7-day planned break) and a  continuous dose cohort of  
ribociclib  administered daily (QD) without a break in each cycle. Tamoxifen will be administered daily 
per standard of care in both cohorts.  
 
 
The primary objective in the phase I study is to confirm safety, tolerability, confirm DLT, and determine 
the RP2D of Ribociclib with Tamoxifen 
The secondary objective is to evaluate 2 dose expansion cohorts after the maximum-tolerated dose 
(MTD) has been reached to better characterize the toxicity profile and identify early signs of efficacy. Our 
goal is to assess the anti-tumor activity Ribociclib + Tamoxifen and to further evaluate their safety in 
adult patients with HR+/HER2- locally advanced or metastatic breast cancer. 
To determine whether treatment with ribociclib improves response rate (RR) compared to the historical 
response rate with treatment with Tamoxifen alone. We know that the expected RR for Tamoxifen after 
failure of first line AI is about 10 % and therefore we hypothesize an improvement of RR to 25%. 
 
  
 
 
Efficacy Evaluation 
 
Response and progression will be evaluated in this study using the new international criteria proposed by 
the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). This will be expanded in protocol. 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 11 
 
 
DEFINITIONS: 
DLT – Dose-Limiting Toxicity 
MTD – Maximum tolerated dose 
PFS – Progression-Free Survival 
DDI – Drug-Drug Interaction 
ER – Estrogen Receptor 
PR – Progesterone Receptor 
HER2 – Human Epithelial Receptor 2 
PO – by mouth (per orum) 
SERMS (selective estrogen receptor modulators) 
SOC – standard of care 
RR- Response  Rate 
FIH – First in human 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 12 
 
 
 
Protocol: 
 
The TEEL Study: A Phase I trial of Tamoxifen with Ribociclib (LEE011) in adult patients with 
advanced ER+ (HER2 negative) breast cancer. 
 
 
1 
BACKGROUND AND RATIONALE 
 
1.1 
Introduction 
 
Breast cancer is one of the most common cancers in the Western Hemisphere and the second most 
common cause of cancer deaths in women. Endocrine therapy, including ovarian ablation; estrogen; and, 
more recently, antiestrogen administration, has been a major component of antitumor therapy in breast 
cancer for more than a century. Hormone sensitive metastatic breast cancer remains a therapeutic 
challenge despite the many recent advances in therapy.  Barring a few exceptions, cure is not achieved in 
this disease.  While hormonal interventions have clearly shown to decrease the tumor burden and to 
prolong life, the majority of patients eventually recurs and succumbs to their disease. 
 
More than two thirds of all the advanced breast cancers are dependent on estrogen. Estrogen-withdrawal 
by physical removal of the ovaries or inhibition of their function has been one of the earliest successful 
interventions against breast cancer; however this intervention was limited to premenopausal women. The 
introduction of the SERMS (selective estrogen receptor modulators) has dramatically improved the 
survival of women with breast cancer, both pre and postmenopausal. The most prominent SERM is 
Tamoxifen, which until recently has been the gold standard for first-line therapy for women with 
advanced hormone-sensitive breast cancer. The introductions of several aromatase inhibitors (AIs) have 
added greatly to the arsenal against breast cancer and have replaced Tamoxifen as first-line therapy. The 
production of estrogen in postmenopausal women requires an enzyme called aromatase. This aromatase 
enzyme has been successfully blocked chemically. The most commonly used aromatase inhibitors include 
letrozole, anastrozole and exemestane.  
 
However, the AIs are reserved for women who have naturally entered menopause or have their ovarian 
function suppressed. For premenopausal women or women who are unable to tolerate AIs, Tamoxifen 
remains the gold standard.  In addition to that, there are many postmenopausal women who cannot 
tolerate the side effect profile of Aromatase Inhibitors. The response rate to first line hormonal therapy 
determined from four pivotal randomized Phase III trials ranges from 20-33% (1, 5, 6, 10). The response 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 13 
 
 
rate to second line hormonal therapy is considerably less (10-20%) (6), suggesting a clear need for more 
effective therapy.    
 
1.2 
Tamoxifen  
 
Tamoxifen is the most commonly used anti-estrogen or SERM; it is currently being used in the 
prevention of breast cancer, for ductal carcinoma in situ, in women with early stage breast cancer and for 
those with metastatic cancer. It is generally well tolerated and due to its extensive use, its toxicities and 
long-term sequelae are well characterized. Women being treated with Tamoxifen may experience flushing 
(similar to those women experience during the menopause), vaginal dryness and vaginal discharge. The 
most serious side effects are the slightly increased risk of thromboembolic events. In a trial involving 900 
women treated with either Tamoxifen or letrozole, 9 out of 455 patients treated with Tamoxifen 
experienced a thromboembolic event (2%), compared to 3 patients out of 455 in the group treated with 
letrozole (<1%). Other side effects included hot flashes (25%), headaches (5%), fatigue (5%) and nausea 
(8%) (5). The observation of endometrial cancer (<0.5%) has been predominantly observed when used in 
the preventive or adjuvant setting (4). Hence, the cumulative administration of Tamoxifen is rarely 
hampered by toxicity but rather by the emergence of resistance suggested by clinical progression while on 
the drug. 
 
 
1.3 
CDK Inhibitors 
 
A promising new class of drugs showing activity in cancer is CDK Inhibitors. Cell cycle progression is 
directly regulated by cyclin-dependent serine-threonine protein kinases. The cyclin D proteins are 
important in cancer, as their abundance and functions are regulated by extracellular growth factor and 
adhesion signaling. The cyclin D proteins act through the CDK4 and CDK6 protein kinases to promote 
G1 progression (1). CDK4 and CDK6, in turn, hyperphosphorylate and activate the retinoblastoma 
protein Rb to promote cell cycle entry and cell proliferation. Consistent with their having an important 
role in human cancer, focal copy number abnormalities that result in increased CDK activity are among 
the most commonly described genetic events observed in diverse tumor types; these events include 
amplifications of the genes that encode cyclin D1 or CDK4, and deletions affecting the CDKN2A locus, 
which encodes the p16INK4a inhibitor of CDK activity (2-4).  
 
Data from The Cancer Genome Atlas highlight the importance of the Cyclin/CDK/Rb pathway in breast 
cancer (2, 3). Abnormalities that result in CDK activation are highly enriched in the luminal A and B 
molecularly defined subgroups, ~85% of which were ER+/Her2- (5). Cyclin D1 amplifications were 
observed in 29% and 58% of the luminal A and B subtypes, respectively, and CDK4 amplifications were 
observed in 14% and 25% of luminal A and B subtypes, respectively. Luminal A subtype tumors also 
have loss of CDKN2C, which encodes p16Ink4a, a CDK inhibitor. The luminal subtypes also maintain 
expression of Rb, which would be essential for benefit from treatment with a CDK4/6 inhibitor (2-4). 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 14 
 
 
PD0332991 is an oral, potent, selective inhibitor of CDK4/6 that was shown to inhibit proliferation and 
induce apoptosis in multiple preclinical models of endocrine-resistant breast cancer, both in vitro and in 
vivo (4, 11). In the clinic, PD0332991 was studied in a randomized Phase II study in combination with 
the non-steroidal aromatase inhibitor letrozole. This combination significantly prolonged median 
progression free survival in postmenopausal women with locally recurrent or advanced ER+/HER2- 
breast cancer treated in the front-line setting (median PFS 26.1 vs 7.5 months, reported in Finn et al (6). 
 
Most breast tumors that initially respond to anti-estrogen therapy acquire resistance in time. Given the 
above pre-clinical data, there may be benefit from a combination of Tamoxifen and Ribociclib, in women 
with hormone sensitive tumors as well as those whose tumors became unresponsive. Current and recently 
completed studies restrict CDK trials and limit the patient population to only postmenopausal patients but 
it is well known that younger, pre-menopausal and peri-menopausal patients often have more 
“aggressive” disease and more endocrine-resistant disease and this combination may be very helpful in 
delaying endocrine resistance in this patient population.  
 
1.4 
Role of the CDK4/6 pathway in breast cancer 
 
Cell cycle progression is directly regulated by cyclin-dependent serine-threonine protein kinases (CDKs). 
Extracellular growth and adhesion signals increase the level and function of cyclin D proteins within the 
cell. In turn, the cyclin D proteins associate with and activate CDK4 and CDK6 (1). CDK4 and CDK6 
phosphorylation leads to inactivation of the retinoblastoma protein (pRb) and thus releases E2F which in 
turn leads to the transcription initiation of proteins involved in cell cycle propagation and cell 
proliferation. The luminal A and B subtypes of breast cancer (85% of which are ER+/HER2-negative) 
have high rates of cyclin D/CDK activation; in the luminal A and B subtypes, cyclin D1 (CCND1) 
amplifications were observed in 29% and 58%, and CDK4 amplifications were observed in 14% and 25% 
respectively (5, 9). 
 
Luminal A subtype tumors also have loss of CDKN2A, which encodes p16Ink4a, a CDK inhibitor (12). 
The luminal subtypes also maintain expression of Rb, which is essential for benefit from treatment with a 
CDK4/6 inhibitor (4). Dysregulation of cell cycle checkpoints is common in cancer. Modulating the cell 
cycle has always been an attractive therapeutic target in cancer, and previously published data have 
suggested that CDK4/6 inhibition may play a key role in the treatment of subsets of breast cancers. 
Patients with HR+ breast cancer exhibiting a gene expression signature of Rb loss had shorter recurrence-
free survival following adjuvant tamoxifen (13). A tumor gene expression signature of E2F activation was 
associated with higher residual tumor cell proliferation following pre-surgical AI therapy. Therefore, 
activation of the CDK4/CDK6/E2F axis promotes endocrine resistance, and treatment with a CDK4/6 
inhibitor or knockdown of CDK4 expression abrogates endocrine-resistant cell proliferation. In 
conclusion, loss of cell cycle control is a hallmark of cancer, and aberrations in the cyclin/CDK/Rb 
pathway are common in breast cancer. Consequently, inhibition of this pathway (at the level of CDK4/6) 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 15 
 
 
leads to reactivation of Rb and binding of E2F, thus leading to cell cycle arrest. Therefore, targeting the 
inhibition of this pathway is considered an attractive therapeutic strategy. Additionally, preclinical and 
clinical data demonstrate that CDK4/6 inhibitors are active in advanced HR+ breast cancer. Palbociclib 
(PD 0332991) is a selective inhibitor of CDK4/6 that inhibits proliferation and induces apoptosis in 
preclinical models of endocrine-resistant breast cancer (4, 11). Preclinical data with palbociclib 
demonstrated synergy with tamoxifen in ER+ breast cancer cell lines; moreover, palbociclib enhanced 
sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade (6). 
 
 
 
2 
INTRODUCTION TO INVESTIGATIONAL TREATMENT(S) 
AND OTHER STUDY TREATMENT(S) 
This study includes RIBOCICLIB, Tamoxifen, and Goserelin (if indicated) 
 
2.1 
Overview of RIBOCICLIB 
 
The ribociclib drug product is planned for oral administration. The available clinical forms are 10 mg, 50 
mg and 200 mg hard gelatin capsules/tablets. The capsules only contain the drug substance; there are no 
excipients.  
Ribociclib should be administered as a flat-fixed dose (400 mg or 600 mg daily), and not by body 
weight or body surface area. 
Patients should be instructed to return unused study drugs to the site at discontinuation or completion of 
treatment. The site personnel will ensure that the appropriate dose of each study drug is administered and 
that the drug accountability is performed. 
In order to minimize the inter-patient variability of PK assessments, ribociclib should be taken as 
follows: 
• 
Patients should be instructed to take the ribociclib capsules with a large glass of water (~250 
ml) at the same time each morning. 
• 
Patients can take meals with their study treatment.  
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 16 
 
 
 
  
 
• 
Based on these data, ribociclib  can be taken without regard to meals. Patients should be 
instructed to swallow the ribociclib capsules whole and not to chew, crush or open them. 
• 
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed before 
the next scheduled dose 
• 
Any doses that are missed (not taken within 6 hours of the intended time) should be skipped 
and should not be replaced or made up on a subsequent day. 
• 
Patients must avoid consumption of grapefruit, Seville oranges or products containing the 
juice of each during the entire study and preferably 7 days before the first dose of study 
medications, due to potential CYP3A4 interaction with the study medications. Orange juice is 
allowed. 
 
2.1.1 
 Nonclinical pharmacokinetics and metabolism 
 
The pharmacokinetics (PK) of ribociclib was investigated in mouse, rat, dog and monkey. The absorption 
of ribociclib  after oral administration was moderate for rats (48-84%). Oral bioavailability (BA) ranged 
between 10% and 65% across animal species. Time to maximum plasma drug concentration (Tmax) was 
between 2 and 4 hours. Terminal half-life (T1/2) of ribociclib was moderate in rodents and monkeys (~2-
5 hours), and was longer in dogs (18 hours). Ribociclib is moderately bound to plasma proteins in all 
animal species with unbound fractions in plasma (fu) ranging from 20-34% (human fu = 30%). [3H 
Ribociclib and metabolites were extensively distributed to tissues in male rats, but there was no uptake 
into the brain. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 
Overview of Tamoxifen 
 
Tamoxifen has been used for over 30 years to treat both pre- and postmenopausal women with HR+ breast cancer. Its 
antitumor effects are thought to be due to its anti-estrogenic activity, mediated by competitive inhibition of estrogen 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 22 
 
 
binding to ER (15). Adjuvant therapy with Tamoxifen for 5 years resulted in a 34% reduction in the annual breast cancer 
death rate, with an absolute reduction in mortality of 9.2% at 15 years (16). 
 
The recommended dose for treatment of breast cancer is 20 mg daily (17). Tamoxifen is generally well tolerated and side 
effects are mainly attributable to estrogen deprivation. However, in some tissues, Tamoxifen acts as an estrogen agonist, 
and these estrogenic effects may be beneficial or detrimental, depending on the target organ. For example, tamoxifen has 
favorable effects on bone health, lipid metabolism and the cardiovascular system, but long-term tamoxifen use is also 
associated with serious, potentially life-threatening adverse events, including invasive endometrial cancer and 
thromboembolic disease (18). 
 
Following oral administration of a single dose of Tamoxifen (20 mg), Tmax was achieved approximately 5 hours post-
dose and concentrations declined with a terminal elimination T1/2 of approximately 5-7 days. Steady-state is achieved for 
Tamoxifen in approximately 4 weeks, while for its metabolite, N-desmethyltamoxifen, steady-state is achieved in 
approximately 8 weeks (17). Tamoxifen metabolism is complex and extensive after oral administration. Tamoxifen is a 
substrate of CYP3A4/5, CYP2D6, and CYP2C9 and an inhibitor of P-glycoprotein (P-gp) (17). Tamoxifen is 
predominantly metabolized by CYP3A4/5 to N-desmethyltamoxifen. A minor route of metabolism occurs via CYP2D6 to 
form the pharmacologically active metabolite, 4- hydroxytamoxifen. These metabolites are further metabolized to several 
secondary metabolites, one of which is the pharmacologically active metabolite, 4-hydroxydesmethyltamoxifen 
(endoxifen), formed mainly via CYP2D6 from N-desmethyltamoxifen. The two pharmacologically active metabolites, 4-
hydroxytamoxifen and endoxifen, are 30- to 100-fold more potent than tamoxifen in terms of ER binding affinity and 
effects on breast cancer cell proliferation and gene expression (19). In breast cancer patients, endoxifen plasma 
concentrations are 5- to 10-fold higher than 4-hydroxytamoxifen (20, 21), suggesting that endoxifen may contribute 
significantly to the overall response to tamoxifen therapy. However, it is also likely that the combined pharmacologic 
activity of tamoxifen and its active metabolites contribute to the clinical efficacy of tamoxifen (19). 
Formation of the pharmacologically active metabolites (4-hydroxytamoxifen and endoxifen) occurs predominantly 
through CYP2D6 (21). Reduced CYP2D6 activity, either through genetic polymorphisms of the enzyme or through 
concomitant administration of drugs that are CYP2D6 inhibitors, could lead to reduced exposure to endoxifen (21, 22). In 
addition, inhibition or induction of CYP3A4 may affect the metabolism of tamoxifen. Based on the prescribing 
information of tamoxifen, no dose adjustment is required for CYP2D6 poor metabolizers or for individuals taking 
medications that are strong inhibitors or inducers of CYP3A4. CYP2D6 poor metabolizer status has been associated with 
poorer invasive disease-free survival in tamoxifen treated patients in a number of studies, though not in others (23). The 
value of CYP2D6 genotyping in tamoxifen therapy is therefore still under investigation and is not standard of care. For 
information on tamoxifen and management of potential tamoxifen related adverse events refer to the Tamoxifen SmPC or 
Prescribing Information. 
 
2.3 
Potential for a drug-drug interaction between Ribociclib and Tamoxifen 
 
The prescribing information for Tamoxifen suggests that Tamoxifen may affect the metabolism of co-administered drugs. 
A significant increase in anticoagulant effect may occur when Tamoxifen is co-administered with coumarin-type 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 23 
 
 
anticoagulants. These medications should be avoided if possible, otherwise careful monitoring of prothrombin time is 
recommended. In addition, tamoxifen has been shown to reduce letrozole plasma concentrations following 
coadministration (17). 
 
Tamoxifen could potentially affect the metabolism of co-administered drugs that are substrates for CYP3A4 since in vitro 
data indicate tamoxifen is a reversible and time-dependent inhibitor of CYP3A4 (24) as well as an inducer of CYP3A4 
(25). Ribociclib is mainly metabolized by CYP3A4 with a minor contribution by FMO3 based on in vitro data. Clinical 
drug interactions studies of tamoxifen and drugs that are mainly metabolized by CYP3A4 (e.g., gefitinib, palbociclib) 
resulted in no significant changes in exposure in the presence of steady-state levels of Tamoxifen when compared with 
exposures when given alone (26, 27). Therefore, based on these in vivo data, Tamoxifen is not expected to affect 
ribociclib PK due to CYP-mediated interactions. Tamoxifen is also an inhibitor of P-gp (17) and could potentially affect 
substrates of this transporter. However, since ribociclib is a low-affinity substrate of P-gp with moderate permeability, 
ribociclib PK is not expected to be significantly affected by inhibition of P-gp by Tamoxifen. 
 
Ribociclib may increase the exposure of co-administered drugs that are substrates for CYP3A4 due to time-dependent 
inhibition of the enzyme. In vitro studies indicate ribociclib is a reversible (Ki = 35 μM) and time-dependent inhibitor (KI 
= 5.06 μM, kinact = 0.0245 min-1) of CYP3A4. Tamoxifen is a substrate of CYP3A4/5, CYP2D6, and CYP2C9 (28). In 
vitro, troleandomycin and ketoconazole (CYP3A4 inhibitors) reduced the formation of N-desmethyltamoxifen (21); 
however the clinical significance is unknown. No clinical studies have been conducted to evaluate the effect of a strong 
inhibitor of CYP3A4/5 on the PK of Tamoxifen. However, the effect of coadministration of strong CYP3A4/5 inducers 
(e.g., rifampicin, aminoglutethimide) with tamoxifen has been evaluated and resulted in reduced concentrations of 
Tamoxifen and its metabolites (20, 29). Based on this information, a potential DDI with coadministration of ribociclib  
cannot be fully excluded. 
 
2.4 
Overview of goserelin 
 
Goserelin (Zoladex®) is a synthetic decapeptide analog of gonadotropin releasing hormone (GnRH) indicated for 
prostatic carcinoma, endometriosis, endometrial thinning, and advanced breast cancer. Goserelin is administered 
subcutaneously every 28 days at a dose of 3.6 mg. Following subcutaneous administration of goserelin (3.6 mg for 2 
months), Tmax was 12-15 days post-dose in males and 8-22 days post-dose in females. The metabolism of goserelin is not 
CYP-mediated; rather it is metabolized by hydrolysis of C-terminal amino acids. More than 90% of a radiolabeled dose 
was excreted in the urine, with approximately 20% of the dose in urine accounted for by unchanged goserelin. The 
adverse events occurring in > 20% of women included hot flushes, headache, sweating, acne, emotional lability, 
depression, decreased libido, vaginitis, breast atrophy, seborrhea and peripheral edema (30). 
 
For information on goserelin and management of goserelin related adverse events refer to the Zoladex® SmPC or 
Prescribing Information. 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 24 
 
 
2.4.1 
Very Low potential for drug-drug interactions with goserelin 
 
The metabolism of goserelin is not CYP-mediated; rather hydrolysis of C-terminal amino acids is the major clearance 
mechanism. No formal clinical DDI studies have been conducted or reported with Goserelin and has been combined with 
Tamoxifen as SOC. Based on the available information, goserelin is not expected to affect the metabolism of nor be 
affected by co-administered drugs (30). 
 
2.5 
Rationale for the combination of CDK4/6 inhibitors with Tamoxifen plus goserelin 
 
Data from The Cancer Genome Atlas highlight the importance of the Cyclin/CDK/Rb pathway in breast cancer (2, 3). 
Abnormalities that result in CDK activation are highly enriched in the luminal A and B molecularly defined subgroups, 
~85% of which were ER+/Her2- (5). Cyclin D1 amplifications were observed in 29% and 58% of the luminal A and B 
subtypes, respectively, and CDK4 amplifications were observed in 14% and 25% of luminal A and B subtypes, 
respectively. Luminal A subtype tumors also have loss of CDKN2C, which encodes p16Ink4a, a CDK inhibitor. The 
luminal subtypes also maintain expression of Rb, which would be essential for benefit from treatment with a CDK4/6 
inhibitor (2-4). PD0332991 is an oral, potent, selective inhibitor of CDK4/6 that was shown to inhibit proliferation and 
induce apoptosis in multiple preclinical models of endocrine-resistant breast cancer, both in vitro and in vivo (4, 11). In 
the clinic, PD0332991 was studied in a randomized Phase II study in combination with the non-steroidal aromatase 
inhibitor letrozole. This combination significantly prolonged median progression free survival in postmenopausal women 
with locally recurrent or advanced ER+/HER2- breast cancer treated in the front-line setting (median PFS 26.1 vs 7.5 
months, reported in Finn et al (6). 
 
Most breast tumors that initially respond to anti-estrogen therapy acquire resistance in time. Given the above pre-clinical 
data, there may be benefit from a combination of Tamoxifen and RIBOCICLIB, in women with hormone sensitive tumors 
as well as those whose tumors became unresponsive. Current and recently completed studies restrict CDK trials and limit 
the patient population to only postmenopausal patients but it is well known that younger, pre-menopausal and peri-
menopausal patients often have more “aggressive” disease and more endocrine-resistant disease and this combination may 
be very helpful in delaying endocrine resistance in this patient population. Multiple adjuvant studies have described 
amenorrhea as a positive prognostic factor in patients with overall survival after adjuvant chemotherapy. Based upon these 
studies, the NCCN guidelines recommend goserelin to be strongly considered in premenopausal women who are 
menstruating despite receiving chemotherapy (7).  
 
In a retrospective study done at one hospital, over 150 patients with stage Ia to IIIa ER + breast cancer who received 
goserelin or chemotherapy were reviewed. Survival analysis was assessed by the Kaplan-Meier method. Survival at 11 
years was significantly better in the goserelin group (P < 0.0012). The lifetime lost was lower in the goserelin group (42 
months vs. 66 months). The quality adjusted survival (QAS) of patients who received goserelin was longer (122.5 ± 6.3 
vs. 112.2 ± 6.7 months. The quality-adjusted life-year was higher in the goserelin group. Goserelin therapy results in 
better survival and higher utility-weighted life-years, and is more cost-effective (8). We plan to add goserelin to all 
women who are not postmenopausal. We estimate that of the 40 patients on study, approximately 20 patients will be post-

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 25 
 
 
menopausal and 20 will not meet the standard criteria of a post-menopausal state (no menstrual cycles for greater than 12 
months and FSH of > 40). 
 
 
3 
OBJECTIVES 
 
3.1 
Primary Objective  
 
Phase I - Confirm DLT:  
The phase I portion of the study is a dose escalation to confirm the safety of the combination and to determine the DLT 
and the RP2D for ribociclib with Tamoxifen. 
 
Phase Ib Dose Expansion:  
Our goal is to further evaluate their safety in adult patients with ER+/HER2- locally advanced or metastatic breast cancer.  
Phase I trials are increasingly including dose-expansion cohorts after the maximum-tolerated dose (MTD) has been 
reached to better characterize the toxicity profile or identify early signs of efficacy within a specific disease population. 
We will evaluate two cohorts in the phase I expansion.  The first will be the standard 21 days of ribociclib dosing with 7 
days rest period and the second will be the continuous dosing (daily). Tamoxifen, per SOC, will be dosed daily in both 
cohorts. We will attempt to assess the anti-tumor activity ribociclib + Tamoxifen. 
 
 
3.2 
Secondary Objectives: 
• Time to progression 
• Overall survival from study initiation at 6 months, 12 months, 18 months and 24 months. 
• Pre-treatment and post-treatment ER receptor expression in tumor in those patients who volunteer for optional 
tissue evaluation.  
• Pharmacokinetics in the dose escalation as well as the dose expansion arms. 
  
4 
INCLUSION CRITERIA  
 
A. Shared Eligibility 
 
1. Histologically and/or cytologically confirmed diagnosis of ER+ and/or PR+ breast cancer by local laboratory.  
2. HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If 
IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.  
3. Patients are allowed (but not required) to have up to two lines of prior chemotherapy regimens in the 
metastatic setting for the dose expansion phase (). For the dose escalation cohort, up to three previous lines of 
chemotherapy in the metastatic setting is acceptable. 
 
4. Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria only for expansion 
cohorts.  

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 26 
 
 
5. For escalation cohorts,bone only disease is allowed. For expansion cohorts, there must be measurable 
disease as stated above (#4)..  
6. ECOG PS 0 or 1.  
7. Written informed consent must be obtained prior to any screening procedures and according to local 
guidelines. 
8. Patient has adequate bone marrow and organ function as defined by the following laboratory values: 
a. Absolute neutrophil count ≥ 1.5 × 109/L. 
b. Platelets ≥ 100 × 109/L. 
c. Hemoglobin ≥ 9 g/dl. 
d. Potassium, total calcium (corrected for serum albumin), magnesium, and sodium  within normal limits for 
the institution or corrected to within normal limits with supplements before first dose of study medication 
e. INR ≤ 1.5. 
f. Serum creatinine ≤ 1.5 ×  ULN or creatinine clearance ≥ 50 mL/min 
g. In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
<2.5 x ULN.  If the patient has liver metastases, ALT and AST < 5 x ULN. 
h. Total bilirubin ≤ ULN; or total bilirubin ≤ 3.0 x ULN or direct bilirubin in patients with well-documented 
Gilbert’s Syndrome 
9. Must be able to swallow ribociclib and Tamoxifen capsules/tablets  
 
B. Pre-menopausal Women Eligibility 
 
1. Premenopausal women who received adjuvant Aromatase Inhibitor and Ovarian Suppression (AI + OS) in the 
adjuvant setting and completed at least 12 months of hormonal therapy. 
2. Pre-menopausal women with de novo metastatic disease are eligible if they have had no prior endocrine 
therapy. 
3. Premenopausal women who have not received Tamoxifen in the metastatic setting. Patients are allowed (but 
not required) to have up to two lines of prior chemotherapy regimens in the metastatic setting for the dose 
expansion phase. For the dose escalation cohort, up to three previous lines of chemotherapy in the metastatic 
setting is acceptable. 
 
 
C. Post-menopausal Women and Men  Eligibility 
 
1. Postmenopausal women or men who have progressed on first-line or second line therapy with an aromatase 
inhibitor in the metastatic setting 
2. Postmenopausal women or men who have recurred while on or after completion of adjuvant treatment with 
aromatase inhibitors (they have completed at least one year of AI in the adjuvant setting before progression on 
AI).  
3. Postmenopausal women or men who are not considered candidates for treatment with an aromatase inhibitory 
by their oncologist, patients not willing to go on AI, or patients who were intolerant to AI.  
10. Postmenopausal women or men are allowed (but not required) to have up to two lines of prior chemotherapy 
regimens in the metastatic setting for the dose expansion phase . For the dose escalation cohort, up to three 
previous lines of chemotherapy in the metastatic setting is acceptable. 
4.  
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 27 
 
 
5 
EXCLUSION CRITERIA 
 
1. Patients with inflammatory breast cancer.  
2. Prior CDK4/6 inhibitor exposure. 
3. Patient has received Tamoxifen in the metastatic setting (for more than 30 days) or has progressed while on 
Tamoxifen in the adjuvant setting.  
4. Patient has a known hypersensitivity to ribociclib or excipients of  tamoxifen.. 
5. Patient has a concurrent malignancy or malignancy within 3 years of starting study drug, with the exception 
of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected 
cervical cancer. 
6. Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria: 
a. At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study 
treatment 
b. Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing 
anti-epileptic medications for brain metastases 
7. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the 
absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, 
malabsorption syndrome, or small bowel resection). 
8. Patient has a known history of HIV infection (testing not mandatory). 
9. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s 
judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or 
compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated 
or uncontrolled fungal, bacterial or viral infections, etc.). 
10. Clinically significant, uncontrolled heart disease and/or a recent events including any of the following: 
a. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery 
bypass grafting, coronary angioplasty, or stenting)  or symptomatic pericarditis within 12 months prior to 
screening. 
b. History of documented congestive heart failure (New York Heart Association functional 
classification III-IV). 
c. Documented cardiomyopathy. 
d. Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated 
acquisition (MUGA) scan or echocardiogram (ECHO) at screening. 
e. History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, 
conduction abnormality in the previous 12 months of screening. 
f. Congenital long QT syndrome or family history of long QT syndrome 
g. Sustained systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening.  Must be corrected or 
controlled prior to starting study. 
h. Bradycardia (heart rate <50 at rest) by ECG or pulse, at screening 
i. 
On screening inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or 
QTcF>_ 450 msec (using Fridericia’s correction). All as determined by screening ECG (mean of triplicate 
ECGs). 
11. Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to 
starting study drug (see Table 7-5) : 
a. Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, 
star-fruit, and Seville oranges. 
b. That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 28 
 
 
c. That have a known risk to prolong the QT interval or induce Torsades de Pointes.  
d. Herbal preparations/medications, dietary supplements, not prescribed by an MD 
12. Patient is currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or 
who have not fully recovered from side effects of such treatment. 
13. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled 
sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular). 
14. Patient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or 
otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed. 
15. Participation in a prior investigational study within 30 days prior to enrollment  
16. Patient who has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to 
starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy 
(exceptions include alopecia) and/or in whom ≥ 25% of the bone marrow was irradiated. 
17. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side 
effects (tumor biopsy is not considered as major surgery). 
18. Patient has not recovered from all toxicities related to prior anticancer therapies to NCI-CTCAE version 4.03 
Grade equal or less than one <1 (Exception to this criterion: patients with any grade of alopecia are allowed to 
enter the study). 
19. Patient with a Child-Pugh score B or C. 
20. Patient has a history of non-compliance to medical regimen or inability to grant consent. 
21. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception 
and until the termination of gestation, confirmed by a positive hCG laboratory test.] 
22. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, 
unless they are using highly effective methods of contraception throughout the study and for 12 weeks after 
study drug discontinuation. Highly effective contraception methods include: 
a. Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not 
acceptable methods of contraception. 
b. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal 
ligation at least six weeks before taking study treatment. In case of tubal ligation alone, only when the 
reproductive status of the woman has been confirmed by follow up hormone level assessment. 
c. Male sterilization (at least 6 months prior to screening). For female patients on the study, the 
vasectomized male partner should be the sole partner for that patient 
d. No patients with HR+ disease should receive hormonal contraception, however the two following 
methods can be combined: Placement of an intrauterine device (IUD) or intrauterine system (IUS and 
barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with 
spermicidal foam/gel/film/cream/ vaginal suppository.  
Note: The use of oral contraception is not allowed. 
Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural 
(spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor 
symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 
six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment is she considered not of child bearing potential.] 
 
6 
PATIENT REGISTRATION: 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 29 
 
 
• 
Patients who meet the eligibility criteria may be registered and enrolled on the trial. We will complete phase I 
portion of the study before proceeding to phase Ib expansion. At time of phase Ib expansion, we will alternate 
enrollment to both cohorts of our study, until both cohorts are complete. 
 
• 
A signed copy of the institution’s IRB-approved informed consent document must be placed on file. 
 
• 
Patients must not start protocol treatment prior to registration. 
 
7 
TREATMENT PLAN:  
 
Investigational Study Treatment 
 
RIBOCICLIB will be supplied by Novartis or its designee in the form of 200 mg hard gelatin capsules/tablets as 
individual patient supply packaged in bottles.  
All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded. 
Dose and treatment schedule 
Study 
treatment 
Pharmaceutical form 
and route of 
administration 
Dose 
Frequency 
and/or Regimen 
RIBOCICLIB 
Capsules/tablets for oral 
use 
400 mg  
21 days on and 
7 days off 
Or 
Daily (in 
continuous cohort) 
RIBOCICLIB 
Capsules/tablets for oral 
use 
600 mg 
21 days on and 
7 days off 
 
RIBOCICLIB will be administered as a flat-fixed dose (400 mg or 600 mg daily), and not by body weight or body 
surface area. 
Patients must be instructed to return unused study drugs to the site at discontinuation or completion of treatment. 
Additionally, patients must be instructed to return empty bottles and/or any unused medication during their 
scheduled study visits to ensure compliance.  The site personnel must ensure that the appropriate dose of each study 
drug is administered and that the drug accountability is performed. 
In order to minimize the inter-patient variability of PK assessments, RIBOCICLIB should be taken as follows: 
• 
Patients should be instructed to take the RIBOCICLIB capsules with a large glass of water (~250 ml) at the 
same time each morning. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 30 
 
 
• 
RIBOCICLIB can be taken without regard to meals; however, dietary habits around the time of dosing should 
be as consistent as possible throughout the study  
• 
No major food effect on RIBOCICLIB exposure is expected. RIBOCICLIB is a high solubility (>30 mg/mL in 
physiological media), high permeability compound with a good dissolution profile at high doses, indicating 
that the exposure of RIBOCICLIB is not likely to be limited by solubility or dissolution. 
• 
Patients should be instructed to swallow the RIBOCICLIB capsules whole and not to chew, crush or open 
them. 
• 
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed before the next 
scheduled dose. 
• 
Any doses that are missed (not taken within 6 hours of the intended time) should be skipped and should not be 
replaced or made up on a subsequent day. 
• 
Patients must avoid consumption of grapefruit, Seville oranges or products containing the juice of each during 
the entire study and preferably 7 days before the first dose of study medications, due to potential CYP3A4 
interaction with the study medications. Orange juice is allowed. 
On days with PK, ECG sampling, chemistry panel and/or lipid panel sampling, the following additional guidelines should 
be followed: 
• 
On a day when PK blood collection is scheduled at the clinic, patients must take study treatment in the clinic 
under the supervision of the Investigator or designee. On all other days patients may take the study treatment at 
home. 
• 
On a day of chemistry panel and/or lipid panel sampling, patients must also take study treatment in the clinic 
under the supervision of the Investigator or designee. On all other days patients may take the study treatment at 
home. 
• 
Pre-dose samples should be drawn prior to dosing. The sampling time of the PK samples and the dosing time 
must be precisely recorded in the CRF. Furthermore, the dosing date and time the study medication was taken on 
the day before the PK assessment must be precisely recorded in the CRF. 
• 
Post-dose PK samples should be collected after dosing of the study treatment. 
• 
A standard 12 lead ECG will be performed after the patient has been resting for 5-10 min prior to each 
time point indicated in study calendar. On cycle 1 day 1 (pre-dose), 3 ECG recordings must be taken at a 
minimum of 2-minute intervals. The combined QTcF values from these 3 ECGs will be averaged to 
provide a single baseline value for each patient. If an abnormal ECG is obtained at any time, patient’s 
electrolytes must be reviewed and repeat ECG measurements must be done after correction of 
electrolyte abnormalities. In the event that a QTcF value of ≥ 501 ms is observed, a blood sample for PK 
will be collected to determine plasma levels of LEE011 and any other identified metabolites 
 
 
 
7.1 
Dose Modifications 
 
 Dose Limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a 
reasonable possibility of relatedness to the study medication, unrelated to disease, disease progression, inter-
current illness, or concomitant medications that occurs within the first 28 days of treatment (cycle 1) with 
RIBOCICLIB and Tamoxifen and meets any of the criteria included in below modification tables. National 
Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for 
all grading. 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 31 
 
 
In this study, a DLT will occur if CTCAE grade 4 neutropenia lasts more than 4 consecutive days, if CTCAE 
grade 3 thrombocytopenia is associated with clinically significant bleeding or if there is grade 4 
thrombocytopenia. Please see the following table (7-1) for other DLT criteria. 
 
 
 
 
 
 
Table 7-1 
Criteria for defining dose-limiting toxicities 
 
TOXICITY 
DLT CRITERIA 
Hematology 
≥ CTCAE grade 4 neutropenia lasting more than 4 consecutive days 
CTCAE grade 3 thrombocytopenia with clinically significant bleeding 
CTCAE grade 4 thrombocytopenia 
Febrile neutropenia (decrease in neutrophils associated with fever, ANC < 1.0 x 10
9/L, 
fever ‡ 38.5°C) 
CTCAE grade 4 lymphopenia lasting more than 7 consecutive days 
Skin and subcutaneous 
tissue disorders 
CTCAE grade 3 Rash > 7 days despite optimal management and does not resolve to Grade 
0 or 1 
CTCAE grade 4 Rash that is thought to be related to study drug 
≥ CTCAE grade 3 photosensitivity 
Metabolism 
Grade 2 hyperglycemia (Fasting glucose 200 – 249 mg/dL) (confirmed with a repeat 
Fasting glucose within 24 hours) that does not resolve to Fasting glucose 
<200 mg/dLwithin 14 consecutive days (despite optimal oral anti-diabetic therapy, 
i.e. glimepiride, glibenclamide and/or metformin) 
Grade 3 hyperglycemia (Fasting glucose 250-499 mg/dL) (confirmed with a repeat Fasting 
glucose within 24 hours) for > 14 consecutive days despite optimal oral anti-diabetic 
treatment 
Grade 4 hyperglycemia (Fasting glucose >499 mg/dL) 
Hyperglycemia leading to diabetic keto-acidosis, hospitalization for IV insulin 
infusion, or non-ketotic coma 
CTCAE grade 3 amylase and/or lipase, not reversible to ≤ CTCAE grade 2 for > 7 
consecutive days 
CTCAE grade 4 amylase and/or lipase 
Gastro-intestinal 
≥ CTCAE grade 3 vomiting ≥ 48 hrs despite optimal anti-emetic therapy 
≥ CTCAE grade 3 diarrhea ≥ 48 hrs despite optimal anti-diarrhea treatment 
≥ CTCAE grade 3 pancreatitis 
Hepato-biliary 
≥ CTCAE grade 3 total bilirubin 
≥ CTCAE grade 3 ALT lasting >4 days (isolated increases in AST without concomitant 
increases in ALT will not be considered dose-limiting, because of the non-specific nature 
of AST) 
≥ CTCAE grade 2 ALT with a ≥ Grade 2 bilirubin elevation of any duration 
≥ CTCAE grade 4 ALT of any duration 
ECG QT Interval 
QTc interval ≥ 501 ms on at least two separate ECGs 
Renal 
≥ CTCAE grade 3 serum creatinine 
Events not described above 
≥ CTCAE grade 3, except for the exclusions noted below 
Exceptions to DLT criteria 
Grade 3 alopecia 
CTCAE grade 3 fatigue < 5 days 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 32 
 
 
CTCAE Grade 3 laboratory abnormalities that are responsive to oral 
supplementation or deemed by the investigator to be clinically insignificant 
CTCAE grade 3 edema <48 hours 
CTCAE version 4.03 will be used for all grading. 
Optimal therapy for vomiting or diarrhea will be based in institutional guidelines, with consideration of the 
prohibited medications listed in this protocol. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 33 
 
 
 
 
 
Table 7-2 Dose modification guidelines 
 
Ribociclib (LEE011) Dose 
Starting dose 
600 mg  
3 x 200 mg 
capsules/tablets 
400 mg  
2 x 200 mg 
capsules/tablets 
First dose reduction 
400 mg 
2 x 200 mg 
capsules/tablets 
200 mg 
1 x 200 mg 
capsules/tablets 
Second dose reduction 
200 mg 
1 x 200 mg 
capsules/tablets 
N/A 
 
There are no scheduled dose reductions for Tamoxifen.  
Table 7-3 Ribociclib dose adjustment and management recommendation for hematological adverse 
reactions 
Toxicity/Grade 
Dose Adjustment and Management 
Recommendations 
Thrombocytopenia 
Grade 1 
(≥75 x 109/L) 
No dose adjustment required. 
Grade 2 
(>50 x 109/L - <75 x 
109/L) 
Dose interruption until recovery to grade 
≤1. 
Re-initiate ribociclib at the same dose. 
Grade 3 
(>25 x 109/L - <50 x 
109/L) 
Dose interruption until recovery to grade 
≤1. 
Re-initiate ribociclib  at the same dose 
level. 
• If toxicity recurs at grade 3: temporary dose 
interruption until recovery to grade ≤1 and reduce 
ribociclib  to the next lower dose level. 
Grade 4 
(<25 x 109/L) 
Dose interruption until recovery to grade ≤1.  
Re-initiate ribociclib at the next lower dose level. 
• If toxicity recurs at grade 4: discontinue 
ribociclib. 
Absolute neutrophil count (ANC) 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 34 
 
 
Grade 1 
(≥1.5 x 109/L) 
No dose adjustment required. 
Grade 2 
(1.0 - <1.5 x 109/L) 
No dose adjustment required. 
Grade 3 
(0.5 - <1.0 x 109/L) 
Dose interruption until recovery to >1.0 x 
109/L. 
Re-initiate ribociclib at the same dose level. 
• If toxicity recurs at grade 3: temporary dose 
interruption until recovery to >1.0 x 109/L. If 
resolved in ≤ 7 days, then maintain dose level. 
If resolved in > 7 days, reduce ribociclib  dose 
to the next lower dose level. 
Grade 4 
(<0.5 x 109/L) 
Dose interruption until recovery to ≥1.0 x 
109/L. 
Re-initiate ribociclib at the next lower dose 
level. 
• If toxicity recurs at grade 4: temporary dose 
interruption until recovery to ≥1.0 x 109/L and 
reduce ribociclib at the next lower dose level. 
Febrile neutropenia 
Grade 3 
ANC <1.0 x 109/L with 
a single temperature of 
>38.3°C (101°F) or a 
sustained temperature 
of ≥38°C (100.4°F) for 
more than one hour 
Dose interruption until improvement of ANC 
≥ 1.0 x 109/L and no fever.  Restart at the next 
lower dose level. 
• If febrile neutropenia recurs, discontinue 
ribociclib. 
Grade 4 
Life-threatening 
consequences; urgent 
intervention indicated 
Discontinue riblocicilb. 
Anemia (Hemoglobin) 
Grade 1 
(≥10.0 – LLN g/dL) 
No dose adjustment required. 
Grade 2 
(≥8.0 – 10.0 g/dL) 
No dose adjustment required. 
Grade 3 
(<8.0 g/dL) 
Dose interruption until recovery to grade ≤ 2. 
Re-initiate RIBOCICLIB at the same dose. 
Grade 4 
Life-threatening 
consequences; urgent 
intervention indicated 
Discontinue ribociclib. 
 
Table 7-4 Recommendations for ribociclib dose modification in case of hepatic toxicities 
 
HEPATOTOXICITY (BILIRUBIN, SGPT/ALT, SGOT/AST) 
TOTAL BILIRUBIN without ALT/AST increase above baseline value 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 35 
 
 
Grade 1 (> ULN – 1.5 x ULN) 
(confirmed 48-to 72hrs later) 
Maintain dose level with LFTs monitored bi-weekly 
Grade 2 (> 1.5 – 3.0 x ULN) 
Dose interruption of ribociclib 
If resolved to ≤ grade 1 in ≤ 21 days, then maintain dose 
level 
If resolved to ≤ grade 1 in > 21 days or toxicity recurs, then 
reduce 1 dose level 
If toxicity recurs after two dose reductions, discontinue 
ribociclib 
Grade 3 (> 3.0 – 10.0 x ULN) 
Dose interruption of ribociclib 
If resolved to ≤ grade 1 in ≤ 21 days, lower 1 dose level of 
ribociclib 
If resolved to ≤ grade 1 in > 21 days or toxicity recurs, 
discontinue ribociclib 
Grade 4 (> 10.0 x ULN) 
Discontinue ribociclib 
Confounding factors and/or alternative causes for increase of total bilirubin should be excluded before dose 
interruption/reduction. They include but are not limited to: evidence of obstruction, such as elevated ALP and GGT typical of 
gall bladder or bile duct disease, hyperbilirubinemia due to the indirect component only (i.e. direct bilirubin component ≤ 1 x 
ULN) due to hemolysis or Gilbert Syndrome, pharmacologic treatment, viral hepatitis, alcoholic or autoimmune hepatitis, 
other hepatotoxic drugs. 
For patients with Gilbert Syndrome, these dose modifications apply to changes in direct bilirubin only. Bilirubin 
will be fractionated if elevated. 
 
 
AST or ALT 
AST or ALT without bilirubin elevation > 2 x ULN 
Same grade as baseline or increase from baseline grade 
0 to grade 1 
(confirmed 48 to 72 hrs later) 
No dose adjustment required with LFTs monitored per 
protocol if same grade as baseline or bi-weekly in case of 
increase from baseline grade 0 to 1 
Increase from baseline grade 0 or 1 to grade 2 (> 3.0 
– 5.0 x ULN) 
or 
from baseline grade 2 to grade 3 (> 5.0 – 20.0 x ULN) 
Dose interruption of ribociclib 
If resolved to ≤ baseline value in ≤ 21 days, then 
maintain dose level 
If resolved to ≤ baseline value in > 21 days or toxicity 
recurs, then reduce 1 dose level 
If toxicity recurs after two dose reductions or recovery to 
≤ baseline value is > 28 days, discontinue RIBOCICLIB 
Increase from baseline grade 0 or 1 to grade 3 (> 5.0 
– 20.0 x ULN) 
Dose interruption of ribociclib until resolved to ≤ baseline 
value, then lower 1 dose level of ribociclib 
If recovery to ≤ baseline value is > 28 days, discontinue 
ribociclib 
If toxicity recurs, discontinue ribociclib 
Grade 4 (> 20.0 x ULN) 
Discontinue ribociclib 
AST or ALT and concurrent Bilirubin 
AST or ALT ≥ grade 2 (> 3 x ULN) in patients with 
normal values at baseline and total bilirubin  > 2 x 
ULN 
or 
AST or ALT ≥ grade 3 (> 5 x ULN) in patients with grade 
1 or 2 at baseline, and total bilirubin  > 2 x ULN 
Discontinue ribociclib 
Confounding factors and/or alternative causes for increased transaminases should be excluded before dose 
interruption/reduction. They include but are not limited to: concomitant medications, herbal preparations or dietary 
supplements, infection, hepato-biliary disorder or obstruction, new or progressive liver metastasis, and alcohol intake. 
Additional follow-up for hepatic toxicities 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 36 
 
 
Hepatic toxicity monitoring includes the following LFTs: albumin, ALT, AST, total bilirubin 
(fractionated if total bilirubin > 2 x ULN), alkaline phosphatase (fractionated if alkaline phosphatase is 
grade 2 or higher) and GGT. For patients with Gilbert Syndrome: total and direct bilirubin must be 
monitored, intensified monitoring applies to changes in direct bilirubin only. 
 
Close observation is recommended in case of AST, ALT, and/or bilirubin increase requiring dose 
interruption, which involves: 
• 
Repeating liver enzyme and serum bilirubin tests two or three times weekly. Frequency of re-testing can 
decrease to once a week or less if abnormalities stabilize or return to normal values. 
• 
Obtaining a more detailed history of current symptoms. 
• 
Obtaining a more detailed history of prior and/or concurrent diseases. 
• 
Obtaining a history of concomitant drug use (including non-prescription medications, herbal and dietary 
supplements), alcohol use, recreational drug use, and special diets. 
• 
Ruling out acute viral hepatitis types A, B, C, D, and E; hepatotropic virus infections (CMV, EBV or HSV); 
autoimmune or alcoholic hepatitis; NASH; hypoxic/ischemic hepatopathy; and biliary tract disease. 
• 
Obtaining a history of exposure to environmental chemical agents. 
• 
Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct bilirubin). 
• 
Considering gastroenterology or hepatology consultations. 
• 
Assessing cardiovascular dysfunction or impaired liver oxygenation, including hypotension or right heart 
failure as possible etiologies for liver dysfunction. 
 
7.2 
Ribociclib dose adjustment and management recommendation for all other adverse 
reactions 
 
Grade Dose Adjustment and Management Recommendations 
1 
No dose adjustment recommended. Initiate appropriate medical therapy and monitor. 
2 
Dose interruption until recovery to grade ≤1. Initiate appropriate medical therapy and 
monitor. 
Re-initiate ribociclib  at the same dose. 
• 
If the same toxicity recurs at grade 2, interrupt ribociclib until recovery to grade ≤1. Re-
initiate ribociclib at the next lower dose level. 
3 
Dose interruption until recovery to grade ≤1. Initiate appropriate medical therapy and 
monitor. 
Re-initiate ribociclib at the next lower dose level. 
• 
If toxicity recurs at grade 2: temporary dose interruption until recovery to grade ≤1 and 
reduce ribociclib dose the next lower dose level. 
• 
If toxicity recurs at grade 3, discontinue RIBOCICLIB. 
4 
Discontinue ribociclib and treat with appropriate medical therapy. 
 
Dose modification guidance in case of QT prolongation 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 37 
 
 
Grade 
Dose Modification 
For all grades 
• 
Check the quality of the ECG. 
• 
Perform analysis of serum electrolytes (K+, Ca++, Phos, Mg++). If below the lower 
limit of normal, interrupt ribociclib administration, correct with supplements or 
appropriate therapy as soon as possible, and repeat electrolytes until documented as 
normal. 
• 
Review concomitant medication usage for the potential to inhibit CYP3A4 and/or to 
prolong the QT interval. 
Check compliance with correct dose and administration of ribociclib. 
1 
QTc 450-480 ms 
No dose adjustment required. 
2 
QTc 481-500 ms 
Interrupt ribociclib 
Perform a repeat ECG one hour after the first QTcF of ≥481ms 
• If QTcF <481 ms, restart ribociclib at the same dose. No dose adjustment required for 
first occurrence. 
• If QTcF remains ≥481 ms, repeat ECG as clinically indicated until the QTcF returns to 
<481 ms. Restart ribociclib at the same dose level. No dose adjustments required for 
first occurrence.  
• If QTcF ≥481 ms recurs, ribociclib should be reduced by 1 dose level (please refer to 
the dosing schedule table)  
Repeat ECGs 7 days and 14 days after dose resumption (then as clinically indicated) 
for any patient who has therapy interrupted due to QTcF ≥481 ms 
3 
QTc ≥ 501 ms on at least two 
separate ECGs 
Interrupt ribociclib 
• Consider consulting a local cardiologist. Perform a repeat ECG one hour after the first 
QTcF of ≥501 ms. 
• If QTcF remains ≥501 ms, repeat ECG as clinically indicated, but at least once a day 
until the QTcF returns to <481 ms. 
• If QTcF returns to <481 ms, ribociclib should be reduced by 1 dose level (please refer 
to the dosing schedule table) 
• Repeat ECGs 7 days and 14 days after dose resumption for any patient who has 
therapy interrupted due to QTcF ≥501 ms 
If QTcF of ≥501 ms recurs, discontinue ribociclib 
4 
QT/QTc ≥ 501 or > 60 ms 
change from baseline 
and 
Torsades de pointes or 
polymorphic ventricular 
tachycardia, or signs/symptoms 
of serious arrhythmia 
Discontinue ribociclib 
• Obtain local cardiologist consultation 
• Perform a repeat ECG  and cardiac monitoring as indicated until the QTcF returns to 
<481 ms. 
Guidance for QTc prolongation 
Management of All Other Adverse Reactions: 
• 
Consider performing an analysis of serum potassium, calcium, phosphorus, and magnesium, for all adverse 
reactions that are potentially associated with electrolyte imbalance (e.g. diarrhea, nausea/vomiting). If 
electrolyte values are below the lower limit of normal, interrupt ribociclib  administration, correct 
electrolytes with supplements as soon as possible, and repeat electrolyte testing until documented 
normalization of the electrolytes 
• 
Check compliance with correct dose and administration of ribociclib. 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 38 
 
 
7.3 
Adjustment of Starting Dose in Special Populations 
 
Renal impairment 
Insufficient data are available to provide a dosage recommendation for ribociclib in patients with renal 
impairment.  
Patients with baseline renal impairment are excluded from the study. Patients who experience renal 
impairment of grade 2 or higher during the treatment period should discontinue treatment and should be 
followed for safety assessments. 
Elderly 
Physicians should exercise caution in monitoring the effects of ribociclib in the elderly. Insufficient data 
are available to provide a dosage recommendation. 
7.4 
Follow-up for toxicities 
Patients who complete treatment or whose treatment is interrupted or permanently discontinued due to an 
adverse event or abnormal laboratory value must be followed at least once a week for 4 weeks, and 
subsequently at 4-week intervals, until resolution or stabilization of the event. All patients will be 
followed up for safety up to 30 days following the last dose of study treatment. 
7.5 
Concomitant Medications 
 
Permitted concomitant therapy 
Medications required to treat AEs, manage cancer symptoms, concurrent diseases and supportive care 
agents, such as pain medications, anti-emetics and anti-diarrheal are allowed. 
The patient must be told to notify the investigational site about any new medications she takes after the 
start of the study treatment.   
Bisphosphonates and denosumab 
Bisphosphonates and denosumab are permitted for the treatment of osteoporosis and prevention of 
skeletal 
related 
events 
for 
patients 
with 
bone 
metastases. 
Chronic 
concomitant 
bisphosphonates/denosumab therapy for the prevention of bone metastasis is not permitted.  
Hematopoietic growth factors 
Hematopoietic growth factors may be used according to ASCO guidelines. 
Palliative radiotherapy 
Palliative radiation is permitted if done solely for bone pain relief. Study treatment will be held during 
XRT and can be resumed thereafter. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 39 
 
 
Refer to the ribociclib Investigator Brochure or tamoxifen package insert  for information on possible 
interactions with other drugs (14). 
 
7.6 
Permitted concomitant therapy requiring caution 
• 
Medications to be used with caution during ribociclib and tamoxifen [in this study are listed below (see 
Table 2). This list is not comprehensive and is only meant to be used as a guide. These medications 
should be excluded from patient use if possible. If they must be given, then use with caution and 
consider a ribociclib interruption if the concomitant medication is only needed for a short time. 
Moderate inhibitors or inducers of CYP3A4/5. 
• 
Strong inhibitors or inducers of P-gP. 
• 
Sensitive substrates of CYP3A4/5 that do not have narrow therapeutic index. 
• 
Strong inhibitors of BSEP. 
• 
Substrates metabolized predominantly by CYP1A2 with a narrow therapeutic index. 
• 
Medications that carry a moderate-low risk for QT prolongation. 
 
7.7 
Prohibited concomitant therapy 
The following medications are prohibited during study treatment in the study (see Table 7-5). This list is 
not comprehensive and is only meant to be used as a guide: 
• 
Strong inhibitors or inducers of CYP3A4/5. 
• 
Substrates of CYP3A4/5 with narrow therapeutic index. 
• 
Medications that carry a known risk for QT prolongation. 
• 
Herbal medications/preparations, dietary supplements. 
• 
Other investigational and antineoplastic therapies not part of the study. 
 
Table 7-5          List of prohibited medications during study drug treatment 
 
• 
 
Category 
Drug Name 
Strong CYP3A4/5 inhibitors 
Boceprevir, clarithromycin, cobicistat, conivaptan, elvitegravir, indinavir, 
itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, 
troleandomycin, voriconazole 
Strong CYP3A4/5 inducers 
Avasimibe2,3, carbamazepine, mitotane, phenobarbital, phenytoin, rifabutin, 
rifampin (rifampicin)3, St. John's wort (hypericum perforatum)3 
Strong CYP2D6 inhibitors 
Bupropion, dacomitinib, ecstasy (MDMA, (3,4- 
methylenedioxymethamphetamine), fluoxetine, paroxetine, quinidine 
CYP3A substrates with NTI1 
Alfentanil, astemizole, cisapride, cyclosporine, diergotamine 
(dihydroergotamine), ergotamine, fentanyl, pimozide, quinidine, sirolimus, 
tacrolimus, terfenadine 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 40 
 
 
Medications with a known risk 
for QT prolongation4 
Amiodarone, arsenic trioxide, astemizole, azithromycin, bepridil, chloroquine, 
chlorpromazine, cisapride, citalopram, clarithromycin, disopyramide, dofetilide, 
domperidone, droperidol, erythromycin, flecainide, halofantrine, haloperidol, ibutilide, 
levomethadyl, mesoridazine, methadone, moxifloxacin, pentamidine, pimozide, 
probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine, 
vavdetanib 
Herbal preparations/ 
medications 
Herbal preparations/medications are prohibited throughout the study. These herbal 
medications include, but are not limited to: St. John’s wort, Kava, ephedra (ma huang), 
gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. 
Patients should stop using these herbal medications 7 days prior to first dose of study 
drug 
Other investigational and 
antineoplastic therapies 
Other investigational therapies must not be used while the patient is on the study. 
Anticancer therapy (chemotherapy, biologic or radiation therapy, and surgery) other 
than the study treatments must not be given to patients while the patient is on the 
study medication. If such agents are required for a patient then the patient must be 
discontinued study drug. 
1 NTI = narrow therapeutic index drugs whose exposure-response indicates that increases in their exposure levels by the 
concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades de Pointes). 
2 Herbal product 
3 
P-gp inducer 
4 
Source www.crediblemeds.org 
 
 
Table 7-6 List of medications to be used with caution during study drug 
treatment 
 
 
Category 
Drug Name 
Moderate CYP3A4/5 inhibitors 
Amprenavir, aprepitant, atazanavir, casopitant, cimetidine, ciprofloxacin, darunavir, 
diltiazem, dronedarone, fluconazole, fosamprenavir, grapefruit juice (citrus paradisi 
fruit juice), imatinib, Schisandra sphenanthera1, tofisopam, 
verapamil 
Moderate CYP3A4/5 inducers 
Bosentan, efavirenz, etravirine, genistein, modafinil, nafcillin, talviraline, 
thioridazine 
P-gp inhibitors 
Captopril, carvedilol, diltiazem, dronedarone, elacridar (GF120918), 
erythromycin, felodipine, fexofenadine, fluvoxamine, milk thistle (silybum 
marianum), nifedipine, nitrendipine, paroxetine, quercetin, ranolazine, Schisandra 
chinensis, talinolol, telmisartan, ticagrelor, tolvaptan, valspodar (PSC 833), 
verapamil 
P-gp inducers 
Any known P-gp inducers 
Sensitive CYP3A4/5 substrates1 
Alpha-dihydroergocryptine, aplaviroc, aprepitant, atorvastatin, brecanavir, brotizolam, 
budesonide, buspirone, capravirine, casopitant, darifenacin, darunavir, dasatinib, 
dronedarone, ebastine, eletriptan, eplerenone, everolimus, felodipine, fluticasone, 
lovastatin, lumefantrine, lurasidone, maraviroc, midazolam, neratinib, nisoldipine, 
perospirone, quetiapine, ridaforolimus, sildenafil, simvastatin, ticagrelor, tolvaptan, 
triazolam, vardenafil, vicriviroc 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 41 
 
 
Strong BSEP inhibitors 
Bosentan, fusidate, glibenclamide, lovastatin, sulindac, troglitazone (TGZ- 
sulfate) 
CYP1A2 substrates with NTI2 
Theophylline, tizanidine 
Medications that carry a 
possible risk for QT 
prolongation 
Alfuzosin, amantadine, atazanavir, chloral hydrate, clozapine, dolasetron, dronedarone, 
eribulin, escitalopram, famotidine, felbamate, fingolimod, foscarnet, fosphenytoin, 
gatifloxacin, gemifloxacin, granisertron, iloperidone, indapamide, isradipine, lapatinib, 
levofloxacin, lithium, moexipril, nicardipine, nilotinib, octreotide, ofloxacin, 
ondansetron, oxytocin, paliperidone, pasireotide, quetiapine, ranolazine, risperidone, 
roxithromycin, sertindole, sunitinib, tamoxifen, tizanidine, vardenafil, venlafaxine, 
ziprasidone 
MATE1 and OCT2 
substrates3 
Acyclovir, amantadine, amiloride, cephalexin, cephradine, cimetidine, famotidine, 
fexofenadine, memantine, metformin (also a substrate for OCT1, MATE1, and 
MATE2K), pindolol, procainamide, ranitidine, and varenciclineRosuvastatin and 
sulfasalazine 
BCRP substrates 
Medications that carry a 
possible risk for QT 
prolongation 
Alfuzosin, amantadine, atazanavir, chloral hydrate, clozapine, dolasetron, dronedarone, 
eribulin, escitalopram, famotidine, felbamate, fingolimod, foscarnet, fosphenytoin, 
gatifloxacin, gemifloxacin, granisertron, iloperidone, indapamide, isradipine, lapatinib, 
levofloxacin, lithium, moexipril, nicardipine, nilotinib, octreotide, ofloxacin, 
ondansetron, oxytocin, paliperidone, pasireotide, quetiapine, ranolazine, risperidone, 
roxithromycin, sertindole, sunitinib, tacrolimus, tamoxifen, telithromycin, tizanidine, 
vardenafil, venlafaxine, voriconazole,  ziprasidoneDaunorubicin, doxorubicin, 
1 Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5-fold or higher when co- 
administered with a potent inhibitor. 
2 NTI = narrow therapeutic index drugs whose exposure-response indicates that increases in their exposure levels by the 
concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades de Pointes). 
3 Source: (31, 32) 
 
 
7.8 
Packaging and labeling 
Study Treatment 
Packaging 
Labeling  
Ribociclib (LEE011) 
 
Tamoxifen  
Capsules in bottles 
 
Prescription tablets 
Labeled as ‘Ribociclib’ 
 
Prescription (SOC) 
 
 
 
7.9 
Drug Supply and Storage 
Study treatments must be received by designated personnel at the study site, handled and stored safely 
and properly, and kept in a secured location to which only the investigator and designated site personnel 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 42 
 
 
have access. Upon receipt, the study treatment should be stored according to the instructions specified on 
the medication label. Medication labels will comply with the legal requirements of each country and be 
printed in the local language. 
 
Supply and storage of study treatment 
Study Treatment 
Supply 
Storage 
Ribociclib (LEE011) 
Bulk supplied by Novartis 
Refer to study treatment 
label 
 
7.10 
Study Drug Compliance and Accountability 
 
Study drug compliance 
Compliance will be assessed by the investigator and/or study personnel at each patient visit and 
information provided by the patient and/or caregiver. Records of study medication used, dosages 
administered, and intervals between visits and the completion of the study will be captured in the Drug 
Accountability Form. This information must be captured in the source document at each patient visit. 
On PK sampling days, compliance will be assured by administration of the study treatment under the 
supervision of investigator or his/her designee, and will be verified by determination of ribociclib in 
plasma. 
Study drug accountability 
The investigator or designee must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability log.  
Disposal and destruction 
The study drug supply can be destroyed at the local Novartis facility, Drug Supply group or third party, as 
appropriate. Study drug destruction at the investigational site will only be permitted if authorized by 
Novartis in a prior agreement and if permitted by local regulations. 
 
8 
TREATMENT PLAN 
 
Phase I/ Phase Ib dose expansion: 
 
TAMOXIFEN: 20 mg PO daily will be given with RIBOCICLIB: 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 43 
 
 
 
Ribociclib (LEE011) 
In phase I: Ribociclib PO starting at a dose of 400 mg po for 21 days of a 28-day treatment cycle; this will 
be increased to 400 mg continuously. We will then evaluate 600 mg po daily for 21 days of a 28 day cycle 
if tolerated. 
If there are no dose limiting toxicities, in the phase I portion, Tamoxifen 20 mg will be given with the 
MTD dose of Ribociclib in 15 patients. This is expected to be 600mg three weeks on and one week off. 
These patients will not be stratified for menopausal status. 
If the 400mg continuous dose was well tolerated in the escalation arm, we will then expand this cohort in 
the phase Ib expansion, we will have an additional cohort of Tamoxifen 20 mg with 400 mg ribociclib  in 
a continuous daily dose in an additional 15 patients. These patients will not be stratified for menopausal 
status.  
Goserelin acetate (Zoladex) (3.6 mg subcutaneous every 28 days) will be given per NCCN guidelines to 
pre-menopausal and peri-menopausal. This will be given on day 1 of every cycle.  We estimate that up to  
20 of 40 patients on this protocol will require goserelin. 
Goserelin is given if patient is premenopausal or peri-menopausal at the time of study entry. 
Premenopausal status is defined as either: 
• 
Patient had last menstrual period within the last 12 months. 
• 
In case of therapy induced amenorrhea, with a plasma estradiol ≥10 pg/mL and/or FSH ≤40IU/l 
or in the premenopausal range according to central laboratory definition. 
• 
Patients who have undergone bilateral oophorectomy do not need goserelin. 
Peri-menopausal status is defined as neither premenopausal nor postmenopausal (see exclusion criteria for 
definition).  
 
8.1 
Study Design: 
 
Dose and Treatment Schedule – Table 8-1 
No of pts 
Cohort Level 
RIBOCICLIB 
Tamoxifen 
3-6 (phase 1) 
1 
400 mg oral days 1-21,  
followed by 1 week break 
 20mg oral daily 
3 -6 (phase 1) 
2  
400mg continuous 
20 mg oral daily 
3 -6 (phase 1) 
3 
600 mg oral day 1-21 followed 
by 1 week break 
20 mg oral daily 
15 (Ib dose 
expansion) 
Phase Ib dose expansion 
600 mg oral day 1-21 followed 
by 1 week break 
20mg oral daily 
15 (Ib dose 
Phase Ib dose expansion- 
400 mg oral daily 
20 mg oral daily 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 44 
 
 
expansion) 
continuous cohort 
 
Ribociclib  
Capsules/tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. 
 
Tamoxifen  
Tablets for oral use 20 mg daily (all days of every cycle without interruption). 
 
Goserelin  
Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle. 
 
The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area. 
All study treatment drugs must be administered together at approximately the same time each day.  
All oral study treatment drugs can be administered with or without food. 
 
The investigator or responsible site personnel should instruct the patient to take the study drugs as per 
protocol (promote compliance). Patients will be instructed to return unused study drugs to the site at 
discontinuation or completion of treatment. The site personnel will ensure that the appropriate dose of 
each study drug is administered and that the drug accountability is performed. 
 
8.2 
Dosing regimen 
 
• 
Ribociclib will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a 
“rest” period from dosing with RIBOCICLIB.  
• 
In the continuous cohort, 400 mg ribociclib will be taken daily (QD). 
• 
Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g. days 1-28 of each 
28 day cycle) Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 
day cycle. This will be given in pre and peri-menopausal women. 
 
 
8.3 
General dosing guidelines 
 
The study treatments should be taken as follows: 
Ribociclib will first be dosed orally for the first 21 days out of a 28 day cycle, then it will be given in a 
continuous dose (in the dose escalation or in the phase I dose expansion), it will be dosed daily of a 28 
day cycle. Tamoxifen is dosed orally daily (28 days out of the 28 day cycle). 
Per SOC, Goserelin is subcutaneously injected on Day 1 of each 28 day cycle. 
Patients should be instructed to take the study treatment of Ribociclib capsules and one tablet of 
Tamoxifen together with a large glass of water (~250 mL) at the same time each morning within 5 
minutes. 
All oral study treatment drugs can be administered with or without food. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 45 
 
 
Patients should be instructed to swallow the capsules and tablets whole and not to chew, crush or open 
them. 
Goserelin should be administered as a subcutaneous injection every 28 days into the anterior abdominal 
wall below the navel line using an aseptic technique under the supervision of a physician or health care 
surrogate. Administration technique should be in accordance with the locally approved label (SmPC). 
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed before the next 
scheduled dose. The occurrence and frequency of any vomiting during a treatment cycle must be noted in 
the adverse events section of the eCRF. 
Any doses that are missed (not taken within 6 hours of the intended time) should be skipped and should 
not be replaced or made up on a subsequent day. 
Patients must avoid consumption of grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges 
or products containing the juice of each during the entire study and preferably for an additional 7 days 
before the first dose of study medications and during the study, due to potential CYP3A4 interaction with 
the study medications. Orange juice is allowed. 
 
8.4 
Safety Evaluation 
Toxicity assessment, interim history and physical exam, CBC and chemistry profile weekly in cycle 1, 
then at day 1 of each cycle for the first 6 months and at least every 2 cycles thereafter.  
 
Adverse Events and other symptoms will be assessed after the subject has had her first dose, and will be 
graded according to the NCI Common Toxicity Criteria version 4.03. Patients will be followed for 
evaluation of safety for at least 30 days after the last dose of study drug. Any study drug-related serious 
adverse events will be followed until resolution, return to baseline grade, or deemed irreversible by the 
Investigator. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 46 
 
 
8.5 
STUDY CALENDAR 
 
TESTS AND VISITS: Table 1-2 
 
Test/ Study 
Baselinec 
C1 
D1 
C1 
D8 
C1 
D15 
C1 
D22 
C2 
D1 
C2 
D22 
C3 
D1 
C3 
D15 
C3 
D16 
C4 
D1 
C4 
D22 
C5 
D1 
C6 
D1 
C6 
D22 
C7 
D1 
C8 
D1 
C8 
D22 
C9 
D1 
C10 
D1 
C10 
D22 
Medical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vital Signs 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Child Pugh Score 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Menopause 
status 
X 
X 
 
 
 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Physical exam 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
 
 
 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Toxicity 
Assessment a 
 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
PK Samples b 
 
 
 
 
 
 
 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
Tumor Biopsy d 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC w/Diff 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
CMPj 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Lipid Panel 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
PT & INR 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uric acid 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FSHk 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDH 
X 
X 
 
 
 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Biomarkers e 
X 
X 
 
 
 
 
X 
X 
 
 
 
X 
X 
 
X 
X 
 
X 
 
 
X 
Urinalysis 
X 
X 
 
 
 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Pregnancy Test f 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staging Scans 
X 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
2D Echo 
X 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
12 Lead EKGi 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 
Disease 
assessmenth 
X 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
Study Drug 
 
X 
 
 
 
X 
 
X 
 
 
X 
 
X 
X 
 
X 
X 
 
X 
X 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 47 
 
 
Dispensing 
 
 
Test/ Study 
C11 
D1 
C12 
D1 
C12 
D22 
C13 
D1 
C14 
D1 
C15 
D1 
C15
D22 
C16 
D1 
C17 
D1 
C18 
D1 
C18 
D22 
C19 
D1 
C20 
D1 
C21 
D1 
C21 
D22 
C22 
D1 
C23 
D1 
C24 
D1 
C24
D22 
30 
day 
F/Ug 
Medical history 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vital Signs 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Menopause status 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Physical exam 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Height 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Toxicity Assessment a 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
PK Samples b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor Biopsy d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
CBC w/Diff 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
CMPj 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Lipid Panel 
 
X 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
PT & INR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uric acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FSHk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDH 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Biomarkers e 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
Urinalysis 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Pregnancy Test f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scans 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
2D Echo 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
12 Lead EKGi 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
Disease assessmenth 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
Study Drug Dispensing 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 48 
 
 
a. Toxicity assessment must be performed until all treatment-related toxicities have been resolved or decreased to grade 1. Adverse events 
must be recorded up to 30 days after termination on study. 
b. PKs to be collected at C3D15 and C3D16 for steady state evaluation at 7 time points: Pre-dose, 0.5 hr post dose, 1 hr post dose, 2 Hrs 
post-dose, 4 Hrs Post dose, 8 hours post dose, 24 hours post dose.  
c. Tests done within 28 days can be used for baseline eligibility.  
d. Tumor Biopsy is optional. Baseline tumor biopsy for predictive markers (optional)  if accessible, if not accessible based on surgical 
evaluation, then archival tissue from metastatic site allowed). Baseline tumor sample will be collected at screening, or following 
progression on prior treatment and prior to C1D1. A newly obtained post-progression tumpr sample for resistance is optional. Should 
patient agree, it will be collected at time of progression and before a new treatment is initiated.  
 
e. Biomarkers to be collected include: CTC, CEA, Ca15-3, Ca 125, Ca 27-29/ (If clinically indicated) at time of restaging scans. Further 
biomarker testing for exploratory circulating tumor DNA will be collected predose on C1D1, predose C3D1, Predose C5D1, and C7D1. 
Biomarkers will also be collected at EOT, or within 15 days of the last dose. 
f. for women of childbearing potential. Pregnancy test will be repeated if clinically indicated. 
g. Thirty day follow up to occur after last dose of study drug. Used for either end of treatment or study completion.  Includes resolution of 
serious adverse events and adverse events related to study treatment. 
h. Disease assessment is determined at visit every 8 weeks after staging scans and tumor marker collection 
i. 
EKG to be done in triplicate. Two minutes apart, after patient has been resting for 5-10 minutes 
j. 
Baseline CMP to include magnesium and phosphorous level for screening criteria. 
k. Female participants only 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 49 
 
 
8.6 
Efficacy Evaluation for Dose I Expansion Cohorts: 
 
Imaging tumor assessments: 
 
Tumor response will be assessed according to RECIST Version 1.1 (Eisenhauer et al 2009). Patients 
should have at least one documented measurable lesion (per RECIST v1.1) or in the absence of 
measurable disease, have at least one predominantly lytic bone lesion at study entry. 
Imaging assessments will be performed at screening within 28 days prior to randomization and 
subsequently every 8 weeks during the first 12 months and every 12 weeks thereafter. See Table 1-2 for 
details of assessments. 
 
 The 8-week (or 12 week) interval should be respected regardless of whether study treatment is 
temporarily withheld. After baseline, all assessments should be performed within ± 7 days of the 
scheduled day of assessment. The same method of assessment and the same technique should be used to 
characterize each individual and reported lesion at baseline and during follow up. 
If a patient discontinues treatment for reasons other than radiological documentation of progression of 
disease, an efficacy assessment should be performed at the time of End of Treatment unless a CT/MRI for 
tumor measurement was performed within 21 days.   
 
All patients will undergo CT or MRI of the chest, abdomen and pelvis at baseline and subsequent 
scheduled visits per Table 1-2. The preferred imaging methodology is CT with intravenous (i.v.) contrast. 
However, if at baseline, a patient is known to have a contraindication to CT i.v. contrast media or 
develops a contraindication during the trial, a non-contrast CT of chest (MRI is not recommended due to 
respiratory artifacts) plus contrast-enhanced MRI (if possible) of abdomen and pelvis should be 
performed. 
 
A whole body bone scan or FDG-PET should be acquired at baseline for all subjects. Skeletal lesions 
identified on the whole body bone scan at baseline, which are not visible on the chest, abdomen and 
pelvis CT (or MRI) scan should be imaged at baseline and followed at scheduled visits using localized 
CT, MRI or x-ray. Whole body bone scans need not be repeated after baseline unless clinically indicated. 
Other metastatic disease sites will be followed by CT or MRI, as clinically indicated. Chest x-ray or 
ultrasound should not be used to assess tumor lesions. Partial Response (PR) and Complete Response 
(CR) must be confirmed by repeat assessments performed not less than 4 weeks and after the criteria for 
objective response are first met. In case tumor assessment is performed <8 weeks from the first 
assessment of an objective response to confirm PR/CR, subsequent tumor assessments should revert back 
to the protocol schedule outlined in study calendar. At the discretion of the Investigators, FDG-PET scans 
may be performed to document progressive disease per RECIST 1.1 (see Appendix 1). If possible, a 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 50 
 
 
single radiologist should perform all tumor response evaluations for an individual patient. Any lesions in 
previously irradiated areas should not be considered measurable unless they have experienced progression 
since the radiotherapy.  
 
8.7 
Treatment Duration 
 
Eligible patients will receive treatment as described above, in consecutive 4-week cycles, until 
progression of disease or unacceptable toxicity. Patients are expected to receive treatment for at least 2 
cycles, at which time the first evaluation for efficacy will occur. If there is continued safety and 
tolerability in the absence of any documented disease progression, treatment may continue for 2 years or 
until progression or non-tolerance.  
Patients will be followed for evaluation of safety for at least 30 days after the last dose of study drug. Any 
study drug-related serious adverse events will be followed until resolution, return to baseline grade, or 
deemed irreversible by the Investigator. 
9 
PHARMACOKINETICS 
 
PK blood samples will be obtained from all patients in both the phase I dose escalation and Ib dose 
expansion (when feasible) for the analysis of plasma concentrations of ribociclib (and any relevant 
metabolites such as LEQ803) and tamoxifen (and any relevant metabolites such as N-
desmethyltamoxifen, 4-hydroxytamoxifen, and endoxifen) to evaluate any potential DDI. PK blood 
samples will be collected at steady-state on Cycle 3 Day 15 & 16 at pre-dose, 0.5, 1, 2, 4, 8 and 24 hrs 
post dose to allow for evaluation of exposure-response (efficacy endpoints and/or safety endpoints) 
relationships.  
 
Steady-state for RIBOCICLIB, Tamoxifen (and metabolites), is generally achieved after daily dosing for 
8 days, 4-8 weeks, 14-40 days, and 7 days, respectively; therefore, an assessment on Cycle 3 Day 15 is 
considered appropriate to evaluate steady-state PK.  
 
Plasma concentrations of RIBOCICLIB and Tamoxifen will be determined by the Clinical Pharmacology 
Laboratory of the Translational Research Core at the Moffitt Cancer Center using LC/MS/MS methods 
that are validated according to ICH/FDA guidelines for bio-analytical analysis. 
 
Tamoxifen with ribociclib will be compared to historical single agent ribociclib PK data, if feasible. If a 
patient discontinues from the study treatment due to toxicities related to study treatment, an unscheduled 
PK blood sample may be obtained as soon as possible after the last dose and the date and time of last dose 
recorded. In addition, an unscheduled blood sample may be collected if additional ECG measurements are 
conducted. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 51 
 
 
 
The date and exact time of dosing on PK collection days, as well as the date and actual time of blood 
sampling must be recorded on the appropriate eCRF pages and PK requisitions. In addition, the exact 
time of dosing on the previous day must be precisely recorded. Any sampling problems (e.g., patient took 
study drug before blood sample, scheduled sampling time is missed, sample is not drawn according to the 
schedule) should be noted as a comment on the eCRF. 
 
If vomiting occurs during the course of treatment, no “re-dosing” of the patient is allowed, and 
medication should resume on the next day. The occurrence and frequency of any vomiting must be noted 
in the adverse events section of the eCRF. In addition, the date and exact time of vomiting should only be 
recorded if it occurs within 4 hours of dosing on the days of full PK sampling. If a vomiting episode 
occurs within the first 4 hours post-dosing during the day of the last dose prior to trough PK sample the 
exact time (whenever possible) must be noted on the eCRF.  
PK parameters, such as Cmax, Tmax, and AUC0-24h, will be estimated (when feasible) from individual 
plasma concentration-time profiles using appropriate methods and software (Phoenix WinNonlin® 
ver6.3). 
 
10 
STATISTICAL CONSIDERATIONS 
 
10.1 
Statistical Considerations for Phase I Study 
 
A standard 3+3 design will be used (33) for the primary toxicity study under Phase I.  A cohort of 3 
patients will be recruited for each dose level at a time at a time.  The first dose level will be level 1 and 
gradually increased to Level 2 and 3 if toxicity AEs are observed within the predefine statistical 
criterion/limit below. 
Level 1: Ribociclib PO starting at a dose of 400 mg po for 21 days, followed by 1 week break of a 28-day 
treatment cycle;  
Level 2: Ribociclib PO treated with a dose of 400 mg po daily for 28 days; 
Level 3: Ribociclilb PO treated with a dose of 600 mg po for 21 days, followed by 1 week break of a 28-
day treatment cycle  
 
 If 1 patient out of 3 experiences a dose limiting toxicity (DLT; see below for definition) at level 1, 3 
additional patients will be recruited at that dose level.  If only 1 out of 6 patients in that dose level 
experiences a DLT, a new cohort of 3 patients will be treated with the next escalated dose level. That is, 
the dose escalation continues until at least two patients among a cohort of three to six patients experience 
dose-limiting toxicities (i.e., ≥ 33% of patients with a dose-limiting toxicity at that dose level).  If 2 out of 
3 or 2 out of 6 patients experience a DLT, no further dose escalation will occur. The recommended phase 
II dose (RP2D) is defined as the dose level at which ≤1/6 patients experience DLT. There will be no dose 
escalation beyond dose level 3, meaning that if ≤1/6 patients experience DLT at this level, dose level will 
become the RP2D. No intra-patient dose escalation is allowed.  Our dose escalation schedule follows a 
modified Fibonacci sequence in which the dose increments become smaller as the dose increases (e.g., the 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 52 
 
 
dose first increases by 100% of the preceding dose, and thereafter by 50%, 33%, and 25% of the 
preceding doses). The RP2D will be defined as the dose level just below this toxic dose level. 
 
Patients who achieve complete response (CR) or partial response (PR) or have stable disease (SD) may 
continue on study treatment until disease progression, as defined by RECIST v1.1 criteria, or intolerable 
toxicity. 
 
10.2 
Statistical Considerations for Phase Ib Dose expansion Study 
If no MTD is observed with Level 1 through 3, we plan to continue/conduct the phase Ib dose expansion 
study as below. This expansion study is planned to understand and obtain initial efficacy data for the 
secondary endpoints.  
Since the identical patient inclusion/exclusion criteria will be used in phase Ib dose expansion, all patient 
data from phase I dose escalation and phase Ib dose expansion studies can be combined for our statistical 
analysis, therefore, the required sample size of patients below will be both for phase I dose escalation and 
phase Ib dose expansion studies.      
 
We obtained our statistical power and required sample size as a single-arm prospective study. In 
particular, for our evaluation of early efficacy we designed the study particular, for our evaluation of early 
efficacy we designed the study for testing H0: P ≤ 0.10 versus H1: P ≥ 0.25at one-sided significance level 
0.05 and power 0.80 as below. 
 
 
 
 
 
Cut-Off  
Actual Actual 
P0 
P1 
Alpha Beta 
R + 1 N 
Alpha Beta 
0.100 0.250 0.050 0.200 8 
40 
0.042 0.182 
 
Where P0 is the maximum response proportion of standard care (tamoxifen alone), P1 is the minimum 
response proportion of our experimental treatment group, and N is the sample size. 
For our statistical testing, if the number of responses ≥ R+1, P0 is rejected based on Fisher’s Exact test 
(34, 35). Alpha is the probability of rejecting that P ≤ P0 when this is true. 
Beta is the probability of rejecting that P ≥ P1 when this is true. 
 
Thus, the study requires 6 subjects under phase I dose escalation and 30 subjects under phase Ib dose 
expansion who will be treated with ribociclib (total 36) in order to test whether the proportion responding, 
P, is less than or equal to 0.100 or greater than or equal to 0.25. If the number of responses is 8 or more, 
the hypothesis that P ≤ 0.100 is rejected with a target Type I error rate, α, of 0.050 and an actual error rate 
of 0.045. The null hypothesis will be rejected if 8 or more responses are observed in 40 patients. This 
design yields a type I error rate of 0.045 and power of 0.818 when the true response rate is 0.25. 
10.3 
Statistical Considerations for Safety  
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 53 
 
 
Toxicity assessment, interim history and physical exam, CBC and chemistry profile weekly in cycle 1, 
then at day 1 of each cycle for the first 6 months and at least every 2 cycle thereafter. Adverse Events and 
other symptoms will be assessed continuously and graded according to the NCI Common Toxicity 
Criteria Version 4.03. Patients will be followed for evaluation of safety for at least 30 days after the last 
dose of study drug. Any study drug-related serious adverse events will be followed until resolution, return 
to baseline grade, or deemed irreversible by the Investigator. 
In this protocol, the routine use of any and all anti-emetics is allowed as clinically appropriate; these 
include the use of dexamethasone and 5-HT3 receptor antagonists. 
. 
 
 
11 
CRITERIA FOR RESPONSE, PROGRESSION AND RELAPSE 
 
Response and progression will be evaluated in this study using the new international criteria proposed by 
the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Committee. (15)  Changes in only the 
largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST 1.1 criteria. 
Note:  Lesions are either measurable or non-measurable using the criteria provided below. The term 
“evaluable” in reference to measurability will not be used because it does not provide additional meaning 
or accuracy. 
For the purposes of this study, patients should be evaluated for response every 8 weeks. In addition to a 
baseline scan, confirmatory scans should also be obtained ≥4 weeks following initial documentation of 
objective response. 
 
11.1 
Criteria for Target Lesions 
 
11.1.1 Measurable disease 
 
Measurable lesions are defined as those that can be accurately measured in at least one 
dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, 
MRI, x-ray) or as >10 mm with spiral CT scan.  All tumor measurements must be recorded 
in millimeters (or decimal fractions of centimeters). 
 
11.1.2. Non-measurable disease 
 
All other lesions (or sites of disease), including small lesions (longest diameter <20 mm with 
conventional techniques or <10 mm using spiral CT scan), are considered non-measurable 
disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, 
lymphangitis cutis/pulmonis, inflammatory breast disease, abdominal masses (not followed 
by CT or MRI), and cystic lesions are all non-measurable. 
 
11.1.3. Target lesions 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 54 
 
 
• All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. 
• Target lesions should be selected on the basis of their size (lesions with the longest diameter) 
and be representative of all involved organs, as well as their suitability for reproducible 
repeated measurements. 
• All measurements should be recorded in metric notation using calipers if clinically assessed. A 
sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum diameters, which will be used 
as reference to further characterize any objective tumor regression in the measurable dimension 
of the disease. If lymph nodes are to be included in the sum, only the short axis will contribute. 
 
11.1.4 Non-target lesions 
 
All lesions (or sites of disease) not identified as target lesions, including pathological lymph 
nodes and all non-measurable lesions, should be identified as non-target lesions and be recorded 
at baseline. 
Measurements of these lesions are not required and they should be followed as ‘present’, 
‘absent’ or in rare cases, ‘unequivocal progression’. 
11.2 
Evaluation of response criteria 
 
11.2.1  Target lesions 
 
Complete Response (CR):     
Disappearance of all target lesions 
 
Partial Response (PR):  
     At least a 30% decrease in the sum of the longest diameter 
(LD) of target lesions, taking as reference the baseline sum 
LD 
 
Progressive Disease (PD):   
At least a 20% increase in the sum of the LD of target 
lesions, taking as reference the smallest sum LD recorded 
since the treatment started or the appearance of one or more 
new lesions 
 
Stable Disease (SD): 
 
     Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest 
sum LD since the treatment started 
 
11.2.2 Evaluation of non-target lesions 
 
Complete Response (CR): Disappearance of all non-target lesions and normalization of 
tumor marker level 
 
Incomplete Response/ 
Stable Disease (SD): 
 
     Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 55 
 
 
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions 
 
11.3 
Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements recorded 
since the treatment started). In general, the patient’s best response assignment will depend on the 
achievement of both measurement and confirmation criteria. 
Note: 
• 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration”. Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
• 
The best overall response for an early death, i.e., a patient who dies without documentation 
of disease progression and before it was time to conduct the first tumor reassessment, will 
be considered unevaluable or not assessed adequately. Response will also be considered 
unevaluable for any patient receiving treatment (regardless of how much was received) 
who did not have any follow-up assessment completed before initiation of alternative 
treatment. These patients must be replaced in both the phase I portion and the phase Ib 
expansion. 
• 
In some circumstances, it may be difficult to distinguish residual disease from normal 
tissue. When the evaluation of complete response depends upon this determination, it is 
recommended that the residual lesion be imaged by PET scan or be investigated by fine 
needle aspirate/biopsy before confirming the complete response status. 
 
 
Target Lesions 
Non-target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/Non-PD 
No 
PR 
PR 
Non-PD 
No 
PR 
SD 
Non-PD 
No 
SD 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
 
11.4 
Guidelines for Evaluation of Measurable Disease 
The same method of assessment and same technique should be used to characterize each identified and 
reported lesion at baseline and during follow-up. Imaging based evaluation is preferred to evaluation by 
clinical examination when both methods have been used to assess antitumor effect of a treatment. 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 56 
 
 
11.4.1 Clinical Lesions  
Clinical lesions will only be considered measurable when they are superficial (e.g., skin 
nodules, palpable lymph nodes). For the case of skin lesions, documentation by color 
photography including a ruler to estimate the size of the lesion is recommended. If measured 
by calipers, measurements have to be confirmed by two independent health care 
professionals. 
 
11.4.2 Conventional CT and MRI  
Conventional CT and MRI should be performed with cuts of 10 mm or less in slice thickness 
contiguously. Spiral CT should be performed using a 5 mm contiguous reconstruction 
algorithm. This applies to the chest, abdomen, and pelvis.  
 
11.5 
Confirmation Measurement/Duration of Response 
 
11.5.1 Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for 
CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease 
is objectively documented (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started). 
The duration of overall complete response is measured from the time measurement criteria 
are first met for CR until the first date that recurrent disease is objectively documented. 
11.5.2 Duration of Stable Disease 
Stable disease is measured from the start of the treatment until the criteria for progression 
are reached, taking as reference the smallest measurements recorded since the treatment 
started. 
 
11.6 
Evaluable disease 
 
Patients must have measurable disease for dose expansion phase. Patients with bone only disease for this 
protocol are eligible if at least one lesion can be measured by MRI that is measurable by RECIST 1.1. 
Tumor markers are not considered measurable.  
 
 
12 
ADVERSE EVENT REPORTING 
 
Investigators are required by Federal Regulations to report serious adverse events. This study will utilize 
the Common Toxicity Criteria version 4.03 to determine the severity of the reaction for adverse event 
reporting. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 57 
 
 
 
A serious adverse event is any adverse drug experience occurring at any dose that: 
 
1. 
results in death; 
2. 
is life-threatening; 
3. 
results in in-patient hospitalization or prolongation of existing hospitalization (admissions for 
elective surgeries or procedure do not qualify); 
4. 
results in a persistent or significant disability/incapacity; or 
5. 
results in congenital anomaly/birth defect. 
 
Reporting requirements and procedures depend upon: (1) whether agents are suspected of causing the 
adverse event, (2) whether the possibility of such an adverse event was reported in the protocol, consent 
form, or manufacturer's literature (expected or unexpected adverse event), (3) the severity or grade of the 
adverse event, (4) the phase of the study and attribution (the determination of whether an adverse event is 
related to a medical treatment or procedure). Any serious adverse event from any cause while a patient is 
receiving treatment on this protocol or up to 30 days after the last dose of protocol treatment has ended 
but which is felt to be treatment related must be reported. 
 
12.1 
Adverse Event Characteristics  
• 
CTCAE term (AE description) and grade:  The descriptions and grading scales found 
in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 
4.03 is utilized for AE reporting.  All appropriate treatment areas should have access to a 
copy of the CTCAE version 4.03.  A copy of the CTCAE version 4.03 can be 
downloaded from the CTEP web site (http://ctep.cancer.gov). 
 
• 
‘Expectedness’: AEs can be ‘Unexpected’ or ‘Expected’ for expedited reporting 
purposes only 
• 
Attribution of the AE: 
- 
Definite – The AE is clearly related to the study treatment. 
- 
Probable – The AE is likely related to the study treatment. 
- 
Possible – The AE may be related to the study treatment. 
- 
Unlikely – The AE is doubtfully related to the study treatment. 
 
 
 
Unrelated – The AE is clearly NOT related to the study treatment. 
 
12.2 Investigator Reporting:  Novartis instructions for rapid notification of serious adverse events 
 
All serious adverse events must be reported to Novartis Pharmaceuticals Drug Safety and 
Epidemiology Department (DS&E) and reporting will be done via the Investigators or his/her 
designee.  
 
All events must be reported, by FAX 
 to Novartis Pharmaceuticals DS&E 
Department within 24 hours of learning of its occurrence. This includes all serious, related, not 
related, labeled (expected) and unlabeled (unexpected) adverse experiences.  
 
All deaths during treatment or within 30 days following completion of active protocol therapy must 
be reported within 24 hours. 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 58 
 
 
Any serious adverse event occurring after the patient has provided informed consent and until 4 
weeks after the patient has stopped study participation must be reported. This includes the period 
in which the study protocol interferes with the standard medical treatment given to a patient (e.g. 
treatment withdrawal during washout period, change in treatment to a fixed dose of concomitant 
medication). 
 
Serious adverse events occurring more than 4 weeks after study discontinuation need only be 
reported if a relationship to the Novartis study drug (or therapy) is suspected.  
 
For Comparator Drugs/Secondary Suspects (Concomitant Medications), all serious adverse 
experiences will be forwarded to the product manufacturer by the investigator. 
Pregnancies 
Any pregnancy that occurs during study participation should be reported by the site. To ensure patient 
safety each pregnancy must also be reported to Novartis within 24 hours of learning of its occurrence. 
The pregnancy should be followed up to determine outcome, including spontaneous or voluntary 
termination, details of birth, and the presence or absence of any birth defects, congenital abnormalities 
or maternal and newborn complications. 
Pregnancy should be recorded on a Clinical Study Pregnancy Form and reported by the investigator to 
the oncology Novartis Drug Safety and Epidemiology (DS&E) department. Pregnancy follow-up 
should be recorded on the same form and should include an assessment of the possible relationship to 
the Novartis study treatment of any pregnancy outcome. Any SAE experienced during pregnancy must 
be reported on the SAE Report Form. 
 
 
13 
DATA SAFETY MONITORING 
 
Adverse events 
Definitions and reporting 
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), 
symptom(s), or medical condition(s) that occur after patient’s signed informed consent has been obtained.  
Abnormal laboratory values or test results occurring after informed consent constitute adverse events only 
if they induce clinical signs or symptoms, are considered clinically significant, require therapy (e.g., 
hematologic abnormality that requires transfusion or hematological stem cell support), or require changes 
in study medication(s). 
Adverse events that begin or worsen after informed consent should be recorded in the Adverse Events 
CRF. Conditions that were already present at the time of informed consent should be recorded in the 
Medical History page of the patient’s CRF. Adverse event monitoring should be continued for at least 30 
days (or 5 half-lives, whichever is longer) following the last dose of study treatment. Adverse events 
(including lab abnormalities that constitute AEs) should be described using a diagnosis whenever 
possible, rather than individual underlying signs and symptoms. When a clear diagnosis cannot be 
identified, each sign or symptom should be reported as a separate Adverse Event. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 59 
 
 
Adverse events will be assessed according to the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the severity of mild, 
moderate, severe, and life-threatening, corresponding to Grades 1 - 4, will be used. 
The occurrence of adverse events should be sought by non-directive questioning of the patient at each 
visit during the study. Adverse events also may be detected when they are volunteered by the patient 
during or between visits or through physical examination, laboratory test, or other assessments. As far as 
possible, each adverse event should be evaluated to determine: 
1. The severity grade (CTCAE Grade 1-4) 
2. Its duration (Start and end dates or if continuing at the Safety Follow-up Visit) 
3. Its relationship to the study treatment (Reasonable possibility that AE is related: No, Yes)  
4. Action taken with respect to study or investigational treatment (none, dose adjusted, temporarily 
interrupted, permanently discontinued, hospitalized, unknown, not applicable) 
5. Whether medication or therapy was given (no concomitant medication/non-drug therapy, concomitant 
medication/non-drug therapy) 
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, recovered/resolved 
with sequalae, fatal, unknown) 
7. Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1 
All adverse events should be treated appropriately. Such treatment may include changes in study drug 
treatment including possible interruption or discontinuation, starting or stopping concomitant treatments, 
changes in the frequency or nature of assessments, hospitalization, or any other medically required 
intervention. Once an adverse event is detected, it should be followed until its resolution, and assessment 
should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected 
relationship to the study drug, the interventions required to treat it, and the outcome. 
Information about common side effects already known about the investigational drug can be found in the 
Investigators’ Brochure (14). This information should be included in the patient informed consent and 
should be discussed with the patient during the study as needed. 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 60 
 
 
Internal Monitoring 
 
 
13.1 
Data Reporting 
  
Data will be captured in Oncore, Moffitt’s Clinical Trials Database.  
Regulatory documents and case report forms will be reviewed routinely by the MCC Clinical Research 
Monitroing Core for accuracy, completeness, and source verification of data entry, validation of 
appropriate informed consent process, adherence to study procedures, and reporting of SAEs and protocol 
deviations according to MCC Monitoring Policies.  
 
 
13.2 
Study Suspension/Termination 
 
The Protocol Monitoring Committee (PMC) and/or the IRB may vote to suspend or terminate approval of 
a research study not being conducted in accordance with the IRB, the Cancer Center and/or regulatory 
requirements or that has been associated with unexpected problems or serious harm to subjects.  The 
PMC/IRB will notify the PI in writing of such suspension or terminations.  It is the responsibility of the 
PMC/IRB Chairperson to ensure prompt written notification of any suspensions or terminations of 
PMC/IRB approval to the relevant Federal Agencies, including OHRP, FDA, the study sponsor/funding 
source and if applicable, the Affiliate Program. 
 
13.3 
Trial Discontinuation 
 
For reasonable cause, the Investigator and/or sponsor (Novartis/Moffitt Cancer Center) may terminate this 
study prematurely. Conditions that may warrant termination include, but are not limited to: the discovery 
of an unexpected, significant, or unacceptable risk to the patients enrolled in the study or if the accrual goals 
are met. A written notification of termination will be issued. 
    
14 
INCLUSION OF PATIENTS AND MINORITIES: 
 
All patients regardless of ethnicity, race or gender are encouraged to participate in clinical trials. This 
trial is a treatment for metastatic breast cancer. Based on the fact that only 1% of all breast cancers occur 
in men, this trial will weighted towards women. Men with breast cancer are encouraged to participate.  
15 
CORRELATIVES 
15.1 Biomarkers in a sub-group of patients 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 61 
 
 
All patients will have the option to provide a representative tumor specimen upon progression. Our goal is 
to attain 10 specimens (volunteers). Patients may supply a tumor specimen that may be from a previous 
biopsy (archival tumor specimen) or a newly obtained tumor specimen. Additionally, a pathology report if 
available must be submitted along with the patient’s archival tumor block/slides.  
Genetic aberrations that lead to a gain in CDK signaling are observed in breast cancer. 
Investigating aberrations of the CDK pathway of patients enrolled in this study will therefore 
allow for the assessment of the potential predictive value of pathway activation for benefit from 
ribociclib in metastatic breast cancer. Biomarkers allowing identification of markers of 
resistance to treatment will also be investigated. 
Tumor and blood samples will be collected according to Table 15-1. 
All assessments will be performed by a Novartis designated laboratory. Instructions for 
collection, preparation and shipment can be found in the laboratory manual. Optional sample 
collection information must be entered on the appropriate eCRF pages and requisition forms. 
Tumor samples will be taken pre-treatment and following progression. Tumor tissue samples 
will be obtained only from patients whose tissue is accessible to minimally invasive biopsy 
(fine needle aspiration, core needle, or superficial excision biopsy). 
The pre-treatment (baseline) biopsy sample may be taken anytime between discontinuation of 
last endocrine therapy or after cytotoxic therapy and the start of study treatment. If not 
accessible, an archival sample from metastatic site is allowed. A pathology report must be 
submitted along with the patient’s archival tumor block/slides.  
Biopsy collection is requested (optional) at time of tumor progression for identifying potential 
markers of lack of response/resistance. 
Tumor samples will be tested retrospectively for Rb protein and PTEN protein by 
immunohistochemistry. The status of molecules (e.g., gene expression, 
mutations, 
amplifications, deletions and/or protein expression/activation etc.) that are involved in the D-
cyclin-CDK4/6-INK4a-Rb and mTOR pathways, such as mutations of CCND1, PIK3CA, PTEN 
and CDK4; gene amplification of CCND1 and CDK4, deletion of CDKN2, as well as potential 
resistant/escape pathways to CDK 4/6 inhibitors and other cancer associated genes, will also be 
investigated in the tumor tissue from all patients (provided that acceptable assays exist), with the 
intention of understanding potential mechanisms of resistance to CDK 4/6 inhibitors and identify 
the patient population that would benefit from this combination.  
The results from these exploratory analyses will be correlated with clinical outcome to 
determine potential predictive biomarkers of ribociclib/everolimus/exemestane response. 
Table 15-1 
Biomarker sample collection plan 
Sample 
Tissue/Volume Visit 
Sample Collection 
Baseline tumor biopsy for 
predictive markers (optional)  if 
accessible, if not accessible 
based on surgical evaluation, 
then archival tissue from 
metastatic site allowed) 
N/A 
Screening 
Following progression on 
prior treatment and prior to 
Cycle 1 Day 1 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 62 
 
 
Newly obtained post-
progression tumor samples for 
resistance (optional) 
N/A 
Post- progression 
At progression and before 
new treatment is initiated 
Exploratory Circulating tumor 
DNA (mandatory) 
Blood/Plasma 
20mL 
Screening or Cycle 1, day 1 Predose 
Blood Plasma 
10mL 
Cycle 3 Day 1 
Cycle 5 Day 1 
Cycle 7 Day 1 
Predose 
Blood/plasma 
20ML 
End of treatment 
Within 15 days from last 
dose 
Biomarkers assessment for pathway inhibition and efficacy 
 Assessments in tumor tissue 
Tumor tissue samples will be collected in this trial for identifying biomarkers that may be 
predictive of benefit from ribociclib + Tamoxifen.  Approximately 15-20 unstained slides 
(minimum of 10) should be made available for biomarker studies. If a biopsy is not possible, 
then an archival Formalin-Fixed, Paraffin-Embedded (FFPE) tumor will be acceptable 
(metastatic lesion preferred). 
All specimens will be sent to a Novartis designated laboratory for analysis. Further details on 
preparation of the tumor biopsies and biomarker analysis will be provided in the Laboratory 
Manual.  
Exploratory circulating tumor DNA 
Assessment of circulating tumor DNA (ctDNA) will allow additional testing for mutations of 
genes that are relevant to HR+ breast cancer (e.g. PIK3CA, AKT, ESR1) and the CDK4/6 
pathway using multiplexed approach such as next generation sequencing. The use of ctDNA offers 
a unique opportunity for serially monitoring tumor mutations in a non-invasive manner during 
the course of treatment, allowing for the detection of changes in tumor burden and monitoring 
response to treatment (Esposito et al 2014). Evaluation of tumor mutations at time of progression 
may provide information regarding potential mechanisms of resistance to therapy with 
ribociclib + tamoxifen. Blood samples for plasma ctDNA will be collected at baseline (20 mL 
at screening or cycle 1 day 1) and then day 1 of cycles 3, 5, 7 and end of treatment (20mL) for 
multiplexed analysis of cancer genes. 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 63 
 
 
 
Exploratory analysis of potential mechanism of resistance 
 
The biopsy collected at progression/end of treatment will be dedicated to understanding 
resistance to treatment. This study provides a unique opportunity to investigate the potential 
mechanisms of resistance to ribociclib in patients. 
The specimens will be handled and shipped as described in the Laboratory Manual. The sample 
collection date must be entered on the appropriate tumor biopsy collection log eCRF page(s) and 
laboratory requisition form(s).  
Additional biomarker assessments 
During the study, in addition to the biomarkers specified above, exploratory research may be 
conducted on any tumor and blood samples collected. These studies would extend the search for 
other potential biomarkers relevant to the effects of ribociclib, goserilin, and Tamoxifen and/or 
prediction of these effects and/or resistance to the treatment, and/or safety. This may include the 
development of ways to detect, monitor or treat cancer. These additional investigations would be 
dependent upon clinical outcome, reagent and sample availability. 
While the goal of the biomarkers is to provide supportive data, this is strictly optional in this 
study. 
 
 
 
 
 
 
 
 
 
 
 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 64 
 
 
16 
REFERENCES 
1. 
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic 
target in cancer. Nat Rev Cancer. 2011;11(8):558-72.  PMID: 21734724. 
2. 
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, 
Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, 
Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-
Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, 
Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson 
AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, 
Getz G, Hidalgo-Miranda A, Meyerson M. Sequence analysis of mutations and translocations across 
breast cancer subtypes. Nature. 2012;486(7403):405-9.  PMID: 22722202. PMCID: 4148686. 
3. 
Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding 
L, Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome 
sequencing. Genome Res. 2012;22(3):568-76.  PMID: 22300766. PMCID: 3290792. 
4. 
Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen 
ES. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast 
cancer. Endocr Relat Cancer. 2011;18(3):333-45.  PMID: 21367843. PMCID: 3624623. 
5. 
Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, 
Bendahl PO, Stal O, Malmstrom P, Ferno M, Ryden L, Hegardt C, Borg A, Ringner M. Global H3K27 
trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012;6(5):494-506.  PMID: 
22766277. PMCID. 
6. 
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst 
C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits 
proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer 
Res. 2009;11(5):R77.  PMID: 19874578. PMCID: 2790859. 
7. 
Wu S, Li Q, Zhu Y, Sun J, Li F, Lin H, Guan X, He Z. Role of goserelin in combination with 
endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for 
hormone receptor: a retrospective matched case-control study. Cancer Biother Radiopharm. 
2013;28(10):697-702.  PMID: 23806020. PMCID: 3833299. 
8. 
Cheng TF, Wang JD, Uen WC. Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant 
chemotherapy in premenopausal women with breast cancer. BMC Cancer. 2012;12:33.  PMID: 
22264299. PMCID: 3296644. 
9. 
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 
2012;490(7418):61-70.  PMID: 23000897. PMCID: 3465532. 
10. 
Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new 
evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009;11(6):112.  PMID: 20067604. 
PMCID: 2815549. 
11. 
Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith 
RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba 
MG, Miller WR, Shyr Y, Arteaga CL. ERalpha-dependent E2F transcription can mediate resistance to 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 65 
 
 
estrogen deprivation in human breast cancer. Cancer Discov. 2011;1(4):338-51.  PMID: 22049316. 
PMCID: 3204388. 
12. 
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, 
Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich 
M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner 
J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, 
Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, 
Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, 
True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 
The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-
905.  PMID: 20164920. PMCID: 2826709. 
13. 
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The 
retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest. 
2007;117(1):218-28.  PMID: 17160137. PMCID: 1679964. 
14. 
Ribociclib IB Ribociclib Investigator’s Brochure. March 18, 2014. 
15. 
Osborne CK. Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. 
Semin Oncol. 1996;23(4 Suppl 9):1.  PMID: 8824458. PMCID. 
16. 
Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for 
early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 
2005;365(9472):1687-717.  PMID: 15894097.  
17. 
Tamoxifen US Prescribing Information. 2005 [updated 2005; cited 2014 October 14]; Available 
from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf  
18. 
Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of 
hormone-responsive early breast cancer. Ann Oncol. 2007;18 Suppl 8:viii26-35.  PMID: 17890211. 
PMCID. 
19. 
Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, 
Skaar TC. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active 
metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85(2):151-9.  PMID: 15111773.  
20. 
Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM. Decreased serum concentrations of 
tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990;50(18):5851-7.  PMID: 
2393854. 
21. 
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, 
Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen 
and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758-64.  
PMID: 14652237.  
22. 
Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat 
Rev Cancer. 2009;9(8):576-86.  PMID: 19629072.  
23. 
Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth 
W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi 

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 66 
 
 
JY, Dieudonne AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, 
Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen 
AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, 
Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, 
Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE, International Tamoxifen Pharmacogenomics C. 
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin 
Pharmacol Ther. 2014;95(2):216-27.  PMID: 24060820. PMCID: 3904554. 
24. 
Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of 
CYP3A enzymes by tamoxifen and metabolites. Xenobiotica. 2002;32(10):863-78.  PMID: 12419016.  
25. 
Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, Buckley AR. Induction of 
cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by 
tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002;30(5):608-12.  PMID: 11950795.  
26. 
Cantarini MV, Macpherson MP, Marshall AL, Robinson AV, Bailey CJ. A phase I study to 
determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib 
(IRESSA) in healthy male volunteers. Cancer Chemother Pharmacol. 2005;56(6):557-62.  PMID: 
16041611.  
27. 
Hoffman JT, O'Gorman M, Loi C, Plotka A, Kirkovsky L, Boutros T, Gallo Stampino C, Wang 
D. A phase 1 open-label fixed-sequence twoperiod crossover study of the effect of multiple doses of 
tamoxifen on palbociclib (PD-0332991) pharmacokinetics in healthy male volunteers (Abstract). Ann 
Oncol. 2014;25(Suppl):i27. 
28. 
Nolvadex US Prescribing Information. 2005 [updated 2005; cited 2014 June 23]; Available from: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf  
29. 
Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de 
Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH. Effects of CYP induction by 
rifampicin on tamoxifen exposure. Clin Pharmacol Ther. 2012;92(1):62-7.  PMID: 22617226.  
30. 
Zoladex US Prescribing Information. 2010 [updated 2010; cited 2014 October 14]; Available 
from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019726s054,020578s032lbl.pdf. 
31. 
US FDA. FDA Draft Guidance for Industry, Drug Interaction Studies – Study Design, Data 
Analysis, and implications for Dosing and Labeling; February 2012. 
32. 
Yonezawa A, Inui K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to 
pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol. 
2011;164(7):1817-25.  PMID: 21457222. PMCID: 3246706. 
33. 
Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45(3):925-37.  PMID: 
2790129.  
34. 
A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20(6):859-
66.  PMID: 11252008.  
35. 
Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 
1982;38(1):143-51.  PMID: 7082756. 
  

TEEL Protocol- Tamoxifen +Ribociclib 
 
Page 67 
 
 
 
 
36. Esposito et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical 
perspectives and research opportunities. Cancer Treatment Reviews. Volume 40, Issue 5, June 2014, 
Pages 648–655. PMID: 24184333